STUDYID,SUBJID,USUBJID,AGE,STR01,STR01N,STR01L,STR02,STR02N,STR02L,TRT01P,TRT01PN,PARAM,PARAMCD,AVAL,CNSR,EVNTDESC,CNSDTDSC,DCTREAS
PSIVISSIG0002,1,PSIVISSIG0002_1,69,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,581,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2,PSIVISSIG0002_2,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1180,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,3,PSIVISSIG0002_3,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1077,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,4,PSIVISSIG0002_4,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,704,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,5,PSIVISSIG0002_5,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,914,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,6,PSIVISSIG0002_6,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,898,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,7,PSIVISSIG0002_7,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,633,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,8,PSIVISSIG0002_8,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,818,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,9,PSIVISSIG0002_9,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,10,PSIVISSIG0002_10,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1501,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,11,PSIVISSIG0002_11,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,347,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,12,PSIVISSIG0002_12,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,905,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,13,PSIVISSIG0002_13,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1378,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,14,PSIVISSIG0002_14,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1095,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,15,PSIVISSIG0002_15,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1077,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,16,PSIVISSIG0002_16,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,140,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,17,PSIVISSIG0002_17,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,245,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,18,PSIVISSIG0002_18,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,787,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,19,PSIVISSIG0002_19,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,299,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,20,PSIVISSIG0002_20,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,121,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,21,PSIVISSIG0002_21,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,536,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,22,PSIVISSIG0002_22,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,236,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,23,PSIVISSIG0002_23,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,24,PSIVISSIG0002_24,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,746,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,25,PSIVISSIG0002_25,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,544,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,26,PSIVISSIG0002_26,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,744,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,27,PSIVISSIG0002_27,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,235,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,28,PSIVISSIG0002_28,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,311,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,29,PSIVISSIG0002_29,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,176,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,30,PSIVISSIG0002_30,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1486,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,31,PSIVISSIG0002_31,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1020,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,32,PSIVISSIG0002_32,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,501,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,33,PSIVISSIG0002_33,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,605,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,34,PSIVISSIG0002_34,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,533,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,35,PSIVISSIG0002_35,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,68,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,36,PSIVISSIG0002_36,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,620,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,37,PSIVISSIG0002_37,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,372,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,38,PSIVISSIG0002_38,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,652,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,39,PSIVISSIG0002_39,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,472,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,40,PSIVISSIG0002_40,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,120,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,41,PSIVISSIG0002_41,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,216,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,42,PSIVISSIG0002_42,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,275,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,43,PSIVISSIG0002_43,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,579,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,44,PSIVISSIG0002_44,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,351,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,45,PSIVISSIG0002_45,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,186,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,46,PSIVISSIG0002_46,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,465,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,47,PSIVISSIG0002_47,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,91,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,48,PSIVISSIG0002_48,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,747,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,49,PSIVISSIG0002_49,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,479,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,50,PSIVISSIG0002_50,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,214,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,51,PSIVISSIG0002_51,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,52,PSIVISSIG0002_52,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,456,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,53,PSIVISSIG0002_53,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,625,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,54,PSIVISSIG0002_54,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,303,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,55,PSIVISSIG0002_55,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,172,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,56,PSIVISSIG0002_56,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1304,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,57,PSIVISSIG0002_57,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,709,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,58,PSIVISSIG0002_58,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,145,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,59,PSIVISSIG0002_59,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,371,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,60,PSIVISSIG0002_60,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,222,0,Death,NA,DEATH
PSIVISSIG0002,61,PSIVISSIG0002_61,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,517,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,62,PSIVISSIG0002_62,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,63,PSIVISSIG0002_63,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,341,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,64,PSIVISSIG0002_64,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,307,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,65,PSIVISSIG0002_65,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1171,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,66,PSIVISSIG0002_66,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,920,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,67,PSIVISSIG0002_67,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,271,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,68,PSIVISSIG0002_68,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,496,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,69,PSIVISSIG0002_69,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1407,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,70,PSIVISSIG0002_70,67,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,920,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,71,PSIVISSIG0002_71,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,237,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,72,PSIVISSIG0002_72,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,589,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,73,PSIVISSIG0002_73,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,278,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,74,PSIVISSIG0002_74,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,692,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,75,PSIVISSIG0002_75,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,983,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,76,PSIVISSIG0002_76,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,352,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,77,PSIVISSIG0002_77,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,394,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,78,PSIVISSIG0002_78,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,133,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,79,PSIVISSIG0002_79,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,774,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,80,PSIVISSIG0002_80,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1005,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,81,PSIVISSIG0002_81,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,82,PSIVISSIG0002_82,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1698,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,83,PSIVISSIG0002_83,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1363,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,84,PSIVISSIG0002_84,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1028,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,85,PSIVISSIG0002_85,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,279,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,86,PSIVISSIG0002_86,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,238,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,87,PSIVISSIG0002_87,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,37,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,88,PSIVISSIG0002_88,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,295,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,89,PSIVISSIG0002_89,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1186,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,90,PSIVISSIG0002_90,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,640,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,91,PSIVISSIG0002_91,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,400,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,92,PSIVISSIG0002_92,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,105,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,93,PSIVISSIG0002_93,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1682,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,94,PSIVISSIG0002_94,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1099,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,95,PSIVISSIG0002_95,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,96,PSIVISSIG0002_96,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,187,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,97,PSIVISSIG0002_97,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,98,PSIVISSIG0002_98,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,479,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,99,PSIVISSIG0002_99,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,352,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,100,PSIVISSIG0002_100,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,182,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,101,PSIVISSIG0002_101,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,746,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,102,PSIVISSIG0002_102,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,705,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,103,PSIVISSIG0002_103,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,834,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,104,PSIVISSIG0002_104,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,507,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,105,PSIVISSIG0002_105,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,405,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,106,PSIVISSIG0002_106,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1785,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,107,PSIVISSIG0002_107,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1165,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,108,PSIVISSIG0002_108,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,456,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,109,PSIVISSIG0002_109,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,354,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,110,PSIVISSIG0002_110,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1189,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,111,PSIVISSIG0002_111,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,177,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,112,PSIVISSIG0002_112,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,302,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,113,PSIVISSIG0002_113,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1308,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,114,PSIVISSIG0002_114,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,535,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,115,PSIVISSIG0002_115,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,738,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,116,PSIVISSIG0002_116,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,699,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,117,PSIVISSIG0002_117,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,230,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,118,PSIVISSIG0002_118,45,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,240,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,119,PSIVISSIG0002_119,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1253,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,120,PSIVISSIG0002_120,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1592,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,121,PSIVISSIG0002_121,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,440,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,122,PSIVISSIG0002_122,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,190,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,123,PSIVISSIG0002_123,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,740,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,124,PSIVISSIG0002_124,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,396,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,125,PSIVISSIG0002_125,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,668,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,126,PSIVISSIG0002_126,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,68,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,127,PSIVISSIG0002_127,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1189,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,128,PSIVISSIG0002_128,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1076,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,129,PSIVISSIG0002_129,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,428,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,130,PSIVISSIG0002_130,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,395,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,131,PSIVISSIG0002_131,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,463,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,132,PSIVISSIG0002_132,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1137,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,133,PSIVISSIG0002_133,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,531,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,134,PSIVISSIG0002_134,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,860,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,135,PSIVISSIG0002_135,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,915,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,136,PSIVISSIG0002_136,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,936,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,137,PSIVISSIG0002_137,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,460,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,138,PSIVISSIG0002_138,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,709,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,139,PSIVISSIG0002_139,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,337,0,Death,NA,DEATH
PSIVISSIG0002,140,PSIVISSIG0002_140,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,461,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,141,PSIVISSIG0002_141,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,347,0,Death,NA,DEATH
PSIVISSIG0002,142,PSIVISSIG0002_142,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,418,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,143,PSIVISSIG0002_143,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,7,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,144,PSIVISSIG0002_144,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,295,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,145,PSIVISSIG0002_145,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1003,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,146,PSIVISSIG0002_146,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,123,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,147,PSIVISSIG0002_147,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,763,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,148,PSIVISSIG0002_148,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,693,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,149,PSIVISSIG0002_149,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,462,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,150,PSIVISSIG0002_150,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1086,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,151,PSIVISSIG0002_151,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,104,0,Death,NA,DEATH
PSIVISSIG0002,152,PSIVISSIG0002_152,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,837,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,153,PSIVISSIG0002_153,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,553,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,154,PSIVISSIG0002_154,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,516,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,155,PSIVISSIG0002_155,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,923,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,156,PSIVISSIG0002_156,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,868,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,157,PSIVISSIG0002_157,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,158,PSIVISSIG0002_158,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,161,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,159,PSIVISSIG0002_159,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1523,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,160,PSIVISSIG0002_160,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,413,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,161,PSIVISSIG0002_161,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,898,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,162,PSIVISSIG0002_162,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1476,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,163,PSIVISSIG0002_163,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,425,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,164,PSIVISSIG0002_164,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,103,0,Death,NA,DEATH
PSIVISSIG0002,165,PSIVISSIG0002_165,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,730,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,166,PSIVISSIG0002_166,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1086,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,167,PSIVISSIG0002_167,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1943,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,168,PSIVISSIG0002_168,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,975,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,169,PSIVISSIG0002_169,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,887,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,170,PSIVISSIG0002_170,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,184,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,171,PSIVISSIG0002_171,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,172,PSIVISSIG0002_172,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1020,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,173,PSIVISSIG0002_173,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,606,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,174,PSIVISSIG0002_174,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,618,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,175,PSIVISSIG0002_175,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,505,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,176,PSIVISSIG0002_176,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,405,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,177,PSIVISSIG0002_177,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,178,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,178,PSIVISSIG0002_178,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1813,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,179,PSIVISSIG0002_179,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,687,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,180,PSIVISSIG0002_180,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,652,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,181,PSIVISSIG0002_181,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,192,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,182,PSIVISSIG0002_182,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,792,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,183,PSIVISSIG0002_183,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,243,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,184,PSIVISSIG0002_184,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,537,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,185,PSIVISSIG0002_185,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,299,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,186,PSIVISSIG0002_186,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1403,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,187,PSIVISSIG0002_187,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,511,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,188,PSIVISSIG0002_188,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,745,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,189,PSIVISSIG0002_189,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,673,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,190,PSIVISSIG0002_190,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,663,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,191,PSIVISSIG0002_191,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,564,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,192,PSIVISSIG0002_192,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1416,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,193,PSIVISSIG0002_193,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,518,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,194,PSIVISSIG0002_194,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,241,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,195,PSIVISSIG0002_195,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,249,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,196,PSIVISSIG0002_196,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,454,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,197,PSIVISSIG0002_197,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1094,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,198,PSIVISSIG0002_198,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,917,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,199,PSIVISSIG0002_199,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,225,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,200,PSIVISSIG0002_200,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1158,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,201,PSIVISSIG0002_201,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,753,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,202,PSIVISSIG0002_202,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,787,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,203,PSIVISSIG0002_203,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,228,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,204,PSIVISSIG0002_204,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,645,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,205,PSIVISSIG0002_205,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1016,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,206,PSIVISSIG0002_206,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,466,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,207,PSIVISSIG0002_207,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,649,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,208,PSIVISSIG0002_208,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,549,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,209,PSIVISSIG0002_209,52,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,236,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,210,PSIVISSIG0002_210,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,292,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,211,PSIVISSIG0002_211,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,679,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,212,PSIVISSIG0002_212,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,131,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,213,PSIVISSIG0002_213,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,340,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,214,PSIVISSIG0002_214,37,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,609,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,215,PSIVISSIG0002_215,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,569,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,216,PSIVISSIG0002_216,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,310,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,217,PSIVISSIG0002_217,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,366,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,218,PSIVISSIG0002_218,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,74,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,219,PSIVISSIG0002_219,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,673,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,220,PSIVISSIG0002_220,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,584,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,221,PSIVISSIG0002_221,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,309,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,222,PSIVISSIG0002_222,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,734,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,223,PSIVISSIG0002_223,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,176,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,224,PSIVISSIG0002_224,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1412,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,225,PSIVISSIG0002_225,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,283,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,226,PSIVISSIG0002_226,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1194,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,227,PSIVISSIG0002_227,52,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,241,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,228,PSIVISSIG0002_228,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1166,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,229,PSIVISSIG0002_229,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,436,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,230,PSIVISSIG0002_230,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,515,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,231,PSIVISSIG0002_231,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,6,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,232,PSIVISSIG0002_232,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,298,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,233,PSIVISSIG0002_233,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,547,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,234,PSIVISSIG0002_234,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1244,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,235,PSIVISSIG0002_235,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,213,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,236,PSIVISSIG0002_236,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,237,PSIVISSIG0002_237,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,350,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,238,PSIVISSIG0002_238,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,130,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,239,PSIVISSIG0002_239,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1483,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,240,PSIVISSIG0002_240,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,241,PSIVISSIG0002_241,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,807,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,242,PSIVISSIG0002_242,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,175,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,243,PSIVISSIG0002_243,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,737,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,244,PSIVISSIG0002_244,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,956,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,245,PSIVISSIG0002_245,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,629,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,246,PSIVISSIG0002_246,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,66,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,247,PSIVISSIG0002_247,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,480,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,248,PSIVISSIG0002_248,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,249,PSIVISSIG0002_249,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1074,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,250,PSIVISSIG0002_250,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1081,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,251,PSIVISSIG0002_251,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,859,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,252,PSIVISSIG0002_252,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,686,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,253,PSIVISSIG0002_253,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,246,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,254,PSIVISSIG0002_254,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1175,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,255,PSIVISSIG0002_255,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,791,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,256,PSIVISSIG0002_256,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,430,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,257,PSIVISSIG0002_257,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,745,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,258,PSIVISSIG0002_258,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,396,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,259,PSIVISSIG0002_259,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,424,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,260,PSIVISSIG0002_260,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1067,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,261,PSIVISSIG0002_261,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1155,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,262,PSIVISSIG0002_262,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1093,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,263,PSIVISSIG0002_263,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,652,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,264,PSIVISSIG0002_264,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,413,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,265,PSIVISSIG0002_265,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1011,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,266,PSIVISSIG0002_266,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,511,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,267,PSIVISSIG0002_267,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,942,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,268,PSIVISSIG0002_268,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,654,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,269,PSIVISSIG0002_269,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,835,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,270,PSIVISSIG0002_270,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,247,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,271,PSIVISSIG0002_271,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,612,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,272,PSIVISSIG0002_272,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,370,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,273,PSIVISSIG0002_273,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1171,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,274,PSIVISSIG0002_274,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,681,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,275,PSIVISSIG0002_275,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,775,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,276,PSIVISSIG0002_276,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,811,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,277,PSIVISSIG0002_277,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,791,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,278,PSIVISSIG0002_278,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,577,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,279,PSIVISSIG0002_279,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,312,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,280,PSIVISSIG0002_280,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1723,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,281,PSIVISSIG0002_281,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,372,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,282,PSIVISSIG0002_282,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,687,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,283,PSIVISSIG0002_283,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1476,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,284,PSIVISSIG0002_284,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,817,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,285,PSIVISSIG0002_285,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,717,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,286,PSIVISSIG0002_286,57,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,573,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,287,PSIVISSIG0002_287,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,607,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,288,PSIVISSIG0002_288,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1482,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,289,PSIVISSIG0002_289,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1085,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,290,PSIVISSIG0002_290,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1516,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,291,PSIVISSIG0002_291,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,740,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,292,PSIVISSIG0002_292,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1098,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,293,PSIVISSIG0002_293,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,376,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,294,PSIVISSIG0002_294,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,315,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,295,PSIVISSIG0002_295,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,259,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,296,PSIVISSIG0002_296,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,755,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,297,PSIVISSIG0002_297,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1183,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,298,PSIVISSIG0002_298,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1440,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,299,PSIVISSIG0002_299,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,839,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,300,PSIVISSIG0002_300,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,301,PSIVISSIG0002_301,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,150,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,302,PSIVISSIG0002_302,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1079,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,303,PSIVISSIG0002_303,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1185,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,304,PSIVISSIG0002_304,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,394,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,305,PSIVISSIG0002_305,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,775,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,306,PSIVISSIG0002_306,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,338,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,307,PSIVISSIG0002_307,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1190,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,308,PSIVISSIG0002_308,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1087,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,309,PSIVISSIG0002_309,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,507,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,310,PSIVISSIG0002_310,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,523,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,311,PSIVISSIG0002_311,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,312,PSIVISSIG0002_312,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1013,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,313,PSIVISSIG0002_313,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,396,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,314,PSIVISSIG0002_314,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,732,0,Death,NA,DEATH
PSIVISSIG0002,315,PSIVISSIG0002_315,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,802,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,316,PSIVISSIG0002_316,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,317,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,317,PSIVISSIG0002_317,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1026,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,318,PSIVISSIG0002_318,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1807,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,319,PSIVISSIG0002_319,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,741,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,320,PSIVISSIG0002_320,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,333,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,321,PSIVISSIG0002_321,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,767,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,322,PSIVISSIG0002_322,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,826,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,323,PSIVISSIG0002_323,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,460,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,324,PSIVISSIG0002_324,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,659,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,325,PSIVISSIG0002_325,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,326,PSIVISSIG0002_326,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,685,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,327,PSIVISSIG0002_327,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,349,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,328,PSIVISSIG0002_328,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,371,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,329,PSIVISSIG0002_329,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,272,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,330,PSIVISSIG0002_330,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,862,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,331,PSIVISSIG0002_331,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,855,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,332,PSIVISSIG0002_332,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,189,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,333,PSIVISSIG0002_333,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,251,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,334,PSIVISSIG0002_334,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,537,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,335,PSIVISSIG0002_335,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1163,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,336,PSIVISSIG0002_336,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,460,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,337,PSIVISSIG0002_337,69,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,293,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,338,PSIVISSIG0002_338,70,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,417,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,339,PSIVISSIG0002_339,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,340,PSIVISSIG0002_340,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,376,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,341,PSIVISSIG0002_341,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,485,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,342,PSIVISSIG0002_342,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,343,PSIVISSIG0002_343,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,122,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,344,PSIVISSIG0002_344,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,656,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,345,PSIVISSIG0002_345,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,650,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,346,PSIVISSIG0002_346,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,735,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,347,PSIVISSIG0002_347,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,348,PSIVISSIG0002_348,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,137,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,349,PSIVISSIG0002_349,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,821,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,350,PSIVISSIG0002_350,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1026,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,351,PSIVISSIG0002_351,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,711,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,352,PSIVISSIG0002_352,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,20,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,353,PSIVISSIG0002_353,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,354,PSIVISSIG0002_354,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,367,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,355,PSIVISSIG0002_355,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,557,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,356,PSIVISSIG0002_356,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,640,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,357,PSIVISSIG0002_357,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1785,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,358,PSIVISSIG0002_358,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,226,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,359,PSIVISSIG0002_359,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,683,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,360,PSIVISSIG0002_360,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,296,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,361,PSIVISSIG0002_361,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,659,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,362,PSIVISSIG0002_362,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,440,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,363,PSIVISSIG0002_363,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,682,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,364,PSIVISSIG0002_364,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,627,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,365,PSIVISSIG0002_365,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,477,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,366,PSIVISSIG0002_366,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,625,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,367,PSIVISSIG0002_367,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1449,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,368,PSIVISSIG0002_368,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,238,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,369,PSIVISSIG0002_369,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,186,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,370,PSIVISSIG0002_370,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1016,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,371,PSIVISSIG0002_371,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,344,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,372,PSIVISSIG0002_372,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,229,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,373,PSIVISSIG0002_373,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,570,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,374,PSIVISSIG0002_374,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1476,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,375,PSIVISSIG0002_375,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,628,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,376,PSIVISSIG0002_376,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,545,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,377,PSIVISSIG0002_377,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,847,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,378,PSIVISSIG0002_378,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1513,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,379,PSIVISSIG0002_379,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,850,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,380,PSIVISSIG0002_380,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,775,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,381,PSIVISSIG0002_381,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,382,PSIVISSIG0002_382,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,788,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,383,PSIVISSIG0002_383,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,415,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,384,PSIVISSIG0002_384,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,236,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,385,PSIVISSIG0002_385,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,856,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,386,PSIVISSIG0002_386,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,243,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,387,PSIVISSIG0002_387,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,159,0,Death,NA,DEATH
PSIVISSIG0002,388,PSIVISSIG0002_388,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,168,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,389,PSIVISSIG0002_389,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,242,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,390,PSIVISSIG0002_390,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1128,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,391,PSIVISSIG0002_391,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,532,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,392,PSIVISSIG0002_392,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,738,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,393,PSIVISSIG0002_393,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,0,Death,NA,DEATH
PSIVISSIG0002,394,PSIVISSIG0002_394,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1095,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,395,PSIVISSIG0002_395,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,943,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,396,PSIVISSIG0002_396,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,411,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,397,PSIVISSIG0002_397,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,339,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,398,PSIVISSIG0002_398,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1293,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,399,PSIVISSIG0002_399,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,744,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,400,PSIVISSIG0002_400,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,402,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,401,PSIVISSIG0002_401,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,397,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,402,PSIVISSIG0002_402,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,896,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,403,PSIVISSIG0002_403,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,552,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,404,PSIVISSIG0002_404,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,193,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,405,PSIVISSIG0002_405,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,302,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,406,PSIVISSIG0002_406,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,733,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,407,PSIVISSIG0002_407,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,420,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,408,PSIVISSIG0002_408,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,616,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,409,PSIVISSIG0002_409,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1176,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,410,PSIVISSIG0002_410,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,59,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,411,PSIVISSIG0002_411,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,695,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,412,PSIVISSIG0002_412,71,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,244,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,413,PSIVISSIG0002_413,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,301,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,414,PSIVISSIG0002_414,66,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,399,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,415,PSIVISSIG0002_415,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,582,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,416,PSIVISSIG0002_416,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,284,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,417,PSIVISSIG0002_417,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,536,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,418,PSIVISSIG0002_418,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,594,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,419,PSIVISSIG0002_419,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1586,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,420,PSIVISSIG0002_420,46,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,270,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,421,PSIVISSIG0002_421,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,585,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,422,PSIVISSIG0002_422,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,816,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,423,PSIVISSIG0002_423,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,127,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,424,PSIVISSIG0002_424,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,615,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,425,PSIVISSIG0002_425,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,814,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,426,PSIVISSIG0002_426,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1196,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,427,PSIVISSIG0002_427,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,852,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,428,PSIVISSIG0002_428,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,429,PSIVISSIG0002_429,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,714,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,430,PSIVISSIG0002_430,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,781,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,431,PSIVISSIG0002_431,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,181,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,432,PSIVISSIG0002_432,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1091,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,433,PSIVISSIG0002_433,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,426,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,434,PSIVISSIG0002_434,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1310,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,435,PSIVISSIG0002_435,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,904,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,436,PSIVISSIG0002_436,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,423,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,437,PSIVISSIG0002_437,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,438,PSIVISSIG0002_438,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,742,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,439,PSIVISSIG0002_439,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,411,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,440,PSIVISSIG0002_440,41,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,503,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,441,PSIVISSIG0002_441,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,295,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,442,PSIVISSIG0002_442,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,256,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,443,PSIVISSIG0002_443,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,941,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,444,PSIVISSIG0002_444,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1284,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,445,PSIVISSIG0002_445,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,314,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,446,PSIVISSIG0002_446,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,375,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,447,PSIVISSIG0002_447,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,813,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,448,PSIVISSIG0002_448,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,606,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,449,PSIVISSIG0002_449,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,894,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,450,PSIVISSIG0002_450,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,43,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,451,PSIVISSIG0002_451,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,851,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,452,PSIVISSIG0002_452,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,302,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,453,PSIVISSIG0002_453,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1394,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,454,PSIVISSIG0002_454,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,663,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,455,PSIVISSIG0002_455,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,568,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,456,PSIVISSIG0002_456,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,521,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,457,PSIVISSIG0002_457,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,340,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,458,PSIVISSIG0002_458,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1016,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,459,PSIVISSIG0002_459,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,399,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,460,PSIVISSIG0002_460,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1184,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,461,PSIVISSIG0002_461,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1041,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,462,PSIVISSIG0002_462,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1412,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,463,PSIVISSIG0002_463,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1298,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,464,PSIVISSIG0002_464,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,667,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,465,PSIVISSIG0002_465,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,379,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,466,PSIVISSIG0002_466,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,406,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,467,PSIVISSIG0002_467,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,468,PSIVISSIG0002_468,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,457,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,469,PSIVISSIG0002_469,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,988,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,470,PSIVISSIG0002_470,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1178,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,471,PSIVISSIG0002_471,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1407,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,472,PSIVISSIG0002_472,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1026,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,473,PSIVISSIG0002_473,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,474,PSIVISSIG0002_474,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1320,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,475,PSIVISSIG0002_475,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,172,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,476,PSIVISSIG0002_476,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,863,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,477,PSIVISSIG0002_477,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1172,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,478,PSIVISSIG0002_478,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,28,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,479,PSIVISSIG0002_479,69,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,583,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,480,PSIVISSIG0002_480,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,739,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,481,PSIVISSIG0002_481,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1012,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,482,PSIVISSIG0002_482,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,70,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,483,PSIVISSIG0002_483,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,630,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,484,PSIVISSIG0002_484,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,299,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,485,PSIVISSIG0002_485,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,318,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,486,PSIVISSIG0002_486,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,367,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,487,PSIVISSIG0002_487,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,307,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,488,PSIVISSIG0002_488,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,901,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,489,PSIVISSIG0002_489,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,349,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,490,PSIVISSIG0002_490,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,263,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,491,PSIVISSIG0002_491,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,693,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,492,PSIVISSIG0002_492,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,559,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,493,PSIVISSIG0002_493,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,235,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,494,PSIVISSIG0002_494,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1208,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,495,PSIVISSIG0002_495,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,426,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,496,PSIVISSIG0002_496,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,497,PSIVISSIG0002_497,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,303,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,498,PSIVISSIG0002_498,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,613,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,499,PSIVISSIG0002_499,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,946,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,500,PSIVISSIG0002_500,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1497,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,501,PSIVISSIG0002_501,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,917,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,502,PSIVISSIG0002_502,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,262,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,503,PSIVISSIG0002_503,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,646,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,504,PSIVISSIG0002_504,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,598,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,505,PSIVISSIG0002_505,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1089,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,506,PSIVISSIG0002_506,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1094,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,507,PSIVISSIG0002_507,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,722,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,508,PSIVISSIG0002_508,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,740,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,509,PSIVISSIG0002_509,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,759,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,510,PSIVISSIG0002_510,66,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,406,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,511,PSIVISSIG0002_511,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,201,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,512,PSIVISSIG0002_512,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,173,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,513,PSIVISSIG0002_513,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1453,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,514,PSIVISSIG0002_514,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,445,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,515,PSIVISSIG0002_515,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1256,0,Death,NA,DEATH
PSIVISSIG0002,516,PSIVISSIG0002_516,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,897,0,Death,NA,DEATH
PSIVISSIG0002,517,PSIVISSIG0002_517,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,682,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,518,PSIVISSIG0002_518,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,913,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,519,PSIVISSIG0002_519,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,442,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,520,PSIVISSIG0002_520,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,436,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,521,PSIVISSIG0002_521,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,946,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,522,PSIVISSIG0002_522,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,743,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,523,PSIVISSIG0002_523,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,788,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,524,PSIVISSIG0002_524,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,458,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,525,PSIVISSIG0002_525,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1306,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,526,PSIVISSIG0002_526,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,512,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,527,PSIVISSIG0002_527,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,733,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,528,PSIVISSIG0002_528,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,399,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,529,PSIVISSIG0002_529,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1387,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,530,PSIVISSIG0002_530,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,531,PSIVISSIG0002_531,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1539,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,532,PSIVISSIG0002_532,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,786,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,533,PSIVISSIG0002_533,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,539,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,534,PSIVISSIG0002_534,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,169,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,535,PSIVISSIG0002_535,72,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,722,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,536,PSIVISSIG0002_536,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,790,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,537,PSIVISSIG0002_537,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,245,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,538,PSIVISSIG0002_538,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,865,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,539,PSIVISSIG0002_539,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,156,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,540,PSIVISSIG0002_540,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,537,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,541,PSIVISSIG0002_541,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,786,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,542,PSIVISSIG0002_542,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1360,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,543,PSIVISSIG0002_543,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,467,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,544,PSIVISSIG0002_544,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,667,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,545,PSIVISSIG0002_545,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1452,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,546,PSIVISSIG0002_546,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,314,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,547,PSIVISSIG0002_547,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,390,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,548,PSIVISSIG0002_548,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1418,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,549,PSIVISSIG0002_549,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1097,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,550,PSIVISSIG0002_550,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1687,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,551,PSIVISSIG0002_551,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,321,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,552,PSIVISSIG0002_552,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,783,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,553,PSIVISSIG0002_553,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,544,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,554,PSIVISSIG0002_554,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,345,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,555,PSIVISSIG0002_555,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1084,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,556,PSIVISSIG0002_556,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,327,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,557,PSIVISSIG0002_557,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1081,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,558,PSIVISSIG0002_558,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,337,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,559,PSIVISSIG0002_559,45,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,253,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,560,PSIVISSIG0002_560,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1517,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,561,PSIVISSIG0002_561,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,314,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,562,PSIVISSIG0002_562,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,232,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,563,PSIVISSIG0002_563,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1882,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,564,PSIVISSIG0002_564,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,810,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,565,PSIVISSIG0002_565,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1008,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,566,PSIVISSIG0002_566,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,288,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,567,PSIVISSIG0002_567,52,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,239,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,568,PSIVISSIG0002_568,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1078,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,569,PSIVISSIG0002_569,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,301,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,570,PSIVISSIG0002_570,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,505,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,571,PSIVISSIG0002_571,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1373,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,572,PSIVISSIG0002_572,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,573,PSIVISSIG0002_573,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,940,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,574,PSIVISSIG0002_574,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,270,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,575,PSIVISSIG0002_575,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,190,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,576,PSIVISSIG0002_576,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1024,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,577,PSIVISSIG0002_577,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,124,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,578,PSIVISSIG0002_578,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,579,PSIVISSIG0002_579,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1365,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,580,PSIVISSIG0002_580,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,937,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,581,PSIVISSIG0002_581,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,132,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,582,PSIVISSIG0002_582,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,286,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,583,PSIVISSIG0002_583,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1141,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,584,PSIVISSIG0002_584,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,674,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,585,PSIVISSIG0002_585,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,65,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,586,PSIVISSIG0002_586,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,149,0,Death,NA,DEATH
PSIVISSIG0002,587,PSIVISSIG0002_587,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1090,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,588,PSIVISSIG0002_588,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,928,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,589,PSIVISSIG0002_589,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,548,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,590,PSIVISSIG0002_590,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,172,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,591,PSIVISSIG0002_591,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,689,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,592,PSIVISSIG0002_592,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1020,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,593,PSIVISSIG0002_593,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,277,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,594,PSIVISSIG0002_594,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,521,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,595,PSIVISSIG0002_595,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,182,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,596,PSIVISSIG0002_596,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,126,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,597,PSIVISSIG0002_597,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1020,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,598,PSIVISSIG0002_598,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,858,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,599,PSIVISSIG0002_599,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,658,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,600,PSIVISSIG0002_600,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1225,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,601,PSIVISSIG0002_601,61,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,613,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,602,PSIVISSIG0002_602,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,137,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,603,PSIVISSIG0002_603,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,843,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,604,PSIVISSIG0002_604,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,683,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,605,PSIVISSIG0002_605,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,526,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,606,PSIVISSIG0002_606,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,794,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,607,PSIVISSIG0002_607,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,556,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,608,PSIVISSIG0002_608,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,310,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,609,PSIVISSIG0002_609,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,891,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,610,PSIVISSIG0002_610,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,198,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,611,PSIVISSIG0002_611,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,691,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,612,PSIVISSIG0002_612,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,687,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,613,PSIVISSIG0002_613,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,867,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,614,PSIVISSIG0002_614,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,885,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,615,PSIVISSIG0002_615,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1001,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,616,PSIVISSIG0002_616,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1193,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,617,PSIVISSIG0002_617,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1477,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,618,PSIVISSIG0002_618,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,731,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,619,PSIVISSIG0002_619,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,299,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,620,PSIVISSIG0002_620,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,457,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,621,PSIVISSIG0002_621,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1155,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,622,PSIVISSIG0002_622,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,476,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,623,PSIVISSIG0002_623,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1449,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,624,PSIVISSIG0002_624,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,813,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,625,PSIVISSIG0002_625,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,153,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,626,PSIVISSIG0002_626,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,627,PSIVISSIG0002_627,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,784,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,628,PSIVISSIG0002_628,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,812,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,629,PSIVISSIG0002_629,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,302,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,630,PSIVISSIG0002_630,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,367,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,631,PSIVISSIG0002_631,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,673,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,632,PSIVISSIG0002_632,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1021,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,633,PSIVISSIG0002_633,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1082,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,634,PSIVISSIG0002_634,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,366,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,635,PSIVISSIG0002_635,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,860,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,636,PSIVISSIG0002_636,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1015,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,637,PSIVISSIG0002_637,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1313,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,638,PSIVISSIG0002_638,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1306,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,639,PSIVISSIG0002_639,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1084,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,640,PSIVISSIG0002_640,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,641,PSIVISSIG0002_641,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,957,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,642,PSIVISSIG0002_642,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,898,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,643,PSIVISSIG0002_643,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,894,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,644,PSIVISSIG0002_644,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,645,PSIVISSIG0002_645,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1372,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,646,PSIVISSIG0002_646,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,699,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,647,PSIVISSIG0002_647,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,508,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,648,PSIVISSIG0002_648,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1061,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,649,PSIVISSIG0002_649,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,114,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,650,PSIVISSIG0002_650,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,106,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,651,PSIVISSIG0002_651,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,322,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,652,PSIVISSIG0002_652,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,813,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,653,PSIVISSIG0002_653,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,654,PSIVISSIG0002_654,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,625,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,655,PSIVISSIG0002_655,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1306,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,656,PSIVISSIG0002_656,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,657,PSIVISSIG0002_657,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,697,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,658,PSIVISSIG0002_658,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1714,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,659,PSIVISSIG0002_659,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1470,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,660,PSIVISSIG0002_660,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1455,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,661,PSIVISSIG0002_661,67,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,915,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,662,PSIVISSIG0002_662,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,268,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,663,PSIVISSIG0002_663,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,262,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,664,PSIVISSIG0002_664,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1156,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,665,PSIVISSIG0002_665,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,805,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,666,PSIVISSIG0002_666,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,667,PSIVISSIG0002_667,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,419,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,668,PSIVISSIG0002_668,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,166,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,669,PSIVISSIG0002_669,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,504,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,670,PSIVISSIG0002_670,62,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,460,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,671,PSIVISSIG0002_671,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1027,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,672,PSIVISSIG0002_672,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,673,PSIVISSIG0002_673,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,175,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,674,PSIVISSIG0002_674,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1322,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,675,PSIVISSIG0002_675,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,447,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,676,PSIVISSIG0002_676,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,988,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,677,PSIVISSIG0002_677,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,701,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,678,PSIVISSIG0002_678,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,943,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,679,PSIVISSIG0002_679,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,517,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,680,PSIVISSIG0002_680,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,607,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,681,PSIVISSIG0002_681,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,555,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,682,PSIVISSIG0002_682,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,171,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,683,PSIVISSIG0002_683,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,696,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,684,PSIVISSIG0002_684,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,685,PSIVISSIG0002_685,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,808,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,686,PSIVISSIG0002_686,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,773,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,687,PSIVISSIG0002_687,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,450,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,688,PSIVISSIG0002_688,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,925,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,689,PSIVISSIG0002_689,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,603,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,690,PSIVISSIG0002_690,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1283,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,691,PSIVISSIG0002_691,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,166,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,692,PSIVISSIG0002_692,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,204,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,693,PSIVISSIG0002_693,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1060,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,694,PSIVISSIG0002_694,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,879,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,695,PSIVISSIG0002_695,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,696,PSIVISSIG0002_696,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,470,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,697,PSIVISSIG0002_697,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,401,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,698,PSIVISSIG0002_698,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,854,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,699,PSIVISSIG0002_699,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1411,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,700,PSIVISSIG0002_700,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,849,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,701,PSIVISSIG0002_701,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,493,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,702,PSIVISSIG0002_702,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,268,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,703,PSIVISSIG0002_703,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,69,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,704,PSIVISSIG0002_704,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,872,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,705,PSIVISSIG0002_705,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,238,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,706,PSIVISSIG0002_706,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,632,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,707,PSIVISSIG0002_707,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,117,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,708,PSIVISSIG0002_708,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,709,PSIVISSIG0002_709,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,660,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,710,PSIVISSIG0002_710,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,318,0,PD,NA,DEATH
PSIVISSIG0002,711,PSIVISSIG0002_711,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,859,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,712,PSIVISSIG0002_712,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1313,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,713,PSIVISSIG0002_713,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,559,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,714,PSIVISSIG0002_714,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1487,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,715,PSIVISSIG0002_715,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,743,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,716,PSIVISSIG0002_716,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,264,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,717,PSIVISSIG0002_717,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,681,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,718,PSIVISSIG0002_718,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,177,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,719,PSIVISSIG0002_719,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,464,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,720,PSIVISSIG0002_720,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,128,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,721,PSIVISSIG0002_721,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,860,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,722,PSIVISSIG0002_722,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,127,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,723,PSIVISSIG0002_723,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,474,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,724,PSIVISSIG0002_724,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,825,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,725,PSIVISSIG0002_725,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1807,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,726,PSIVISSIG0002_726,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,286,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,727,PSIVISSIG0002_727,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,194,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,728,PSIVISSIG0002_728,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,581,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,729,PSIVISSIG0002_729,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,686,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,730,PSIVISSIG0002_730,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1188,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,731,PSIVISSIG0002_731,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,278,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,732,PSIVISSIG0002_732,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,182,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,733,PSIVISSIG0002_733,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,633,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,734,PSIVISSIG0002_734,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,464,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,735,PSIVISSIG0002_735,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1017,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,736,PSIVISSIG0002_736,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,456,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,737,PSIVISSIG0002_737,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,241,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,738,PSIVISSIG0002_738,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,700,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,739,PSIVISSIG0002_739,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,181,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,740,PSIVISSIG0002_740,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,627,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,741,PSIVISSIG0002_741,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,239,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,742,PSIVISSIG0002_742,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,235,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,743,PSIVISSIG0002_743,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,291,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,744,PSIVISSIG0002_744,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,432,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,745,PSIVISSIG0002_745,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,342,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,746,PSIVISSIG0002_746,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1066,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,747,PSIVISSIG0002_747,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,476,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,748,PSIVISSIG0002_748,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,749,PSIVISSIG0002_749,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,649,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,750,PSIVISSIG0002_750,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,850,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,751,PSIVISSIG0002_751,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1024,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,752,PSIVISSIG0002_752,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,288,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,753,PSIVISSIG0002_753,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,158,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,754,PSIVISSIG0002_754,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,565,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,755,PSIVISSIG0002_755,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,275,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,756,PSIVISSIG0002_756,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,344,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,757,PSIVISSIG0002_757,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,128,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,758,PSIVISSIG0002_758,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1182,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,759,PSIVISSIG0002_759,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1091,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,760,PSIVISSIG0002_760,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,802,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,761,PSIVISSIG0002_761,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,856,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,762,PSIVISSIG0002_762,66,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,409,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,763,PSIVISSIG0002_763,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,639,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,764,PSIVISSIG0002_764,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,922,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,765,PSIVISSIG0002_765,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,358,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,766,PSIVISSIG0002_766,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,751,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,767,PSIVISSIG0002_767,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,277,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,768,PSIVISSIG0002_768,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,911,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,769,PSIVISSIG0002_769,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,933,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,770,PSIVISSIG0002_770,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1875,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,771,PSIVISSIG0002_771,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,564,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,772,PSIVISSIG0002_772,57,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,574,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,773,PSIVISSIG0002_773,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,441,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,774,PSIVISSIG0002_774,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,775,PSIVISSIG0002_775,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,479,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,776,PSIVISSIG0002_776,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1196,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,777,PSIVISSIG0002_777,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,762,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,778,PSIVISSIG0002_778,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,566,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,779,PSIVISSIG0002_779,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,841,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,780,PSIVISSIG0002_780,69,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,570,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,781,PSIVISSIG0002_781,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,782,PSIVISSIG0002_782,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,749,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,783,PSIVISSIG0002_783,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,547,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,784,PSIVISSIG0002_784,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,439,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,785,PSIVISSIG0002_785,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,151,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,786,PSIVISSIG0002_786,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,293,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,787,PSIVISSIG0002_787,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,452,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,788,PSIVISSIG0002_788,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1413,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,789,PSIVISSIG0002_789,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,394,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,790,PSIVISSIG0002_790,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1078,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,791,PSIVISSIG0002_791,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,804,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,792,PSIVISSIG0002_792,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,736,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,793,PSIVISSIG0002_793,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,246,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,794,PSIVISSIG0002_794,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,795,PSIVISSIG0002_795,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,177,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,796,PSIVISSIG0002_796,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,902,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,797,PSIVISSIG0002_797,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,315,0,PD,NA,DEATH
PSIVISSIG0002,798,PSIVISSIG0002_798,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,427,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,799,PSIVISSIG0002_799,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1133,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,800,PSIVISSIG0002_800,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1026,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,801,PSIVISSIG0002_801,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1353,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,802,PSIVISSIG0002_802,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,667,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,803,PSIVISSIG0002_803,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,394,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,804,PSIVISSIG0002_804,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,806,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,805,PSIVISSIG0002_805,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,844,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,806,PSIVISSIG0002_806,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,363,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,807,PSIVISSIG0002_807,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1514,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,808,PSIVISSIG0002_808,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,228,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,809,PSIVISSIG0002_809,71,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,232,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,810,PSIVISSIG0002_810,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,788,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,811,PSIVISSIG0002_811,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,370,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,812,PSIVISSIG0002_812,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1678,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,813,PSIVISSIG0002_813,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,400,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,814,PSIVISSIG0002_814,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,577,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,815,PSIVISSIG0002_815,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,575,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,816,PSIVISSIG0002_816,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1178,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,817,PSIVISSIG0002_817,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,236,0,Death,NA,DEATH
PSIVISSIG0002,818,PSIVISSIG0002_818,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1015,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,819,PSIVISSIG0002_819,70,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,417,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,820,PSIVISSIG0002_820,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,130,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,821,PSIVISSIG0002_821,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,793,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,822,PSIVISSIG0002_822,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1173,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,823,PSIVISSIG0002_823,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,404,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,824,PSIVISSIG0002_824,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,141,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,825,PSIVISSIG0002_825,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,249,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,826,PSIVISSIG0002_826,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,827,PSIVISSIG0002_827,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1126,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,828,PSIVISSIG0002_828,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1048,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,829,PSIVISSIG0002_829,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1389,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,830,PSIVISSIG0002_830,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,821,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,831,PSIVISSIG0002_831,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,805,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,832,PSIVISSIG0002_832,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,313,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,833,PSIVISSIG0002_833,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,129,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,834,PSIVISSIG0002_834,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,323,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,835,PSIVISSIG0002_835,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,415,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,836,PSIVISSIG0002_836,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,548,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,837,PSIVISSIG0002_837,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,289,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,838,PSIVISSIG0002_838,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1197,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,839,PSIVISSIG0002_839,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,706,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,840,PSIVISSIG0002_840,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,841,PSIVISSIG0002_841,73,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,710,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,842,PSIVISSIG0002_842,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,328,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,843,PSIVISSIG0002_843,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,806,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,844,PSIVISSIG0002_844,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,457,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,845,PSIVISSIG0002_845,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,846,PSIVISSIG0002_846,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,780,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,847,PSIVISSIG0002_847,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,251,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,848,PSIVISSIG0002_848,67,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,910,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,849,PSIVISSIG0002_849,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1682,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,850,PSIVISSIG0002_850,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1297,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,851,PSIVISSIG0002_851,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1190,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,852,PSIVISSIG0002_852,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,416,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,853,PSIVISSIG0002_853,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1219,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,854,PSIVISSIG0002_854,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1947,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,855,PSIVISSIG0002_855,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,174,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,856,PSIVISSIG0002_856,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,716,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,857,PSIVISSIG0002_857,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,924,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,858,PSIVISSIG0002_858,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,275,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,859,PSIVISSIG0002_859,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,689,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,860,PSIVISSIG0002_860,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,543,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,861,PSIVISSIG0002_861,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1419,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,862,PSIVISSIG0002_862,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,341,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,863,PSIVISSIG0002_863,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1086,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,864,PSIVISSIG0002_864,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,139,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,865,PSIVISSIG0002_865,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,675,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,866,PSIVISSIG0002_866,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,439,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,867,PSIVISSIG0002_867,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,782,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,868,PSIVISSIG0002_868,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1075,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,869,PSIVISSIG0002_869,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,610,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,870,PSIVISSIG0002_870,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,717,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,871,PSIVISSIG0002_871,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,770,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,872,PSIVISSIG0002_872,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,802,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,873,PSIVISSIG0002_873,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,851,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,874,PSIVISSIG0002_874,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,459,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,875,PSIVISSIG0002_875,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,252,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,876,PSIVISSIG0002_876,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,447,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,877,PSIVISSIG0002_877,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1174,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,878,PSIVISSIG0002_878,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,682,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,879,PSIVISSIG0002_879,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1044,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,880,PSIVISSIG0002_880,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,904,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,881,PSIVISSIG0002_881,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,741,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,882,PSIVISSIG0002_882,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,243,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,883,PSIVISSIG0002_883,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1102,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,884,PSIVISSIG0002_884,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1774,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,885,PSIVISSIG0002_885,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,784,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,886,PSIVISSIG0002_886,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,234,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,887,PSIVISSIG0002_887,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1362,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,888,PSIVISSIG0002_888,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,140,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,889,PSIVISSIG0002_889,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,123,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,890,PSIVISSIG0002_890,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1215,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,891,PSIVISSIG0002_891,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,305,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,892,PSIVISSIG0002_892,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,613,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,893,PSIVISSIG0002_893,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,674,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,894,PSIVISSIG0002_894,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1449,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,895,PSIVISSIG0002_895,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,719,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,896,PSIVISSIG0002_896,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,495,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,897,PSIVISSIG0002_897,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,703,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,898,PSIVISSIG0002_898,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1248,0,Death,NA,DEATH
PSIVISSIG0002,899,PSIVISSIG0002_899,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,733,0,Death,NA,DEATH
PSIVISSIG0002,900,PSIVISSIG0002_900,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,908,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,901,PSIVISSIG0002_901,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,902,PSIVISSIG0002_902,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,818,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,903,PSIVISSIG0002_903,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,294,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,904,PSIVISSIG0002_904,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,971,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,905,PSIVISSIG0002_905,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,295,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,906,PSIVISSIG0002_906,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1395,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,907,PSIVISSIG0002_907,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,249,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,908,PSIVISSIG0002_908,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,469,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,909,PSIVISSIG0002_909,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,924,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,910,PSIVISSIG0002_910,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,791,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,911,PSIVISSIG0002_911,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,343,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,912,PSIVISSIG0002_912,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,882,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,913,PSIVISSIG0002_913,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,831,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,914,PSIVISSIG0002_914,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,470,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,915,PSIVISSIG0002_915,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,558,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,916,PSIVISSIG0002_916,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1309,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,917,PSIVISSIG0002_917,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,579,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,918,PSIVISSIG0002_918,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,451,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,919,PSIVISSIG0002_919,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,183,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,920,PSIVISSIG0002_920,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1414,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,921,PSIVISSIG0002_921,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,582,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,922,PSIVISSIG0002_922,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1181,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,923,PSIVISSIG0002_923,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,642,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,924,PSIVISSIG0002_924,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,73,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,925,PSIVISSIG0002_925,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,257,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,926,PSIVISSIG0002_926,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,480,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,927,PSIVISSIG0002_927,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,738,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,928,PSIVISSIG0002_928,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1463,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,929,PSIVISSIG0002_929,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1475,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,930,PSIVISSIG0002_930,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,655,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,931,PSIVISSIG0002_931,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,704,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,932,PSIVISSIG0002_932,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,845,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,933,PSIVISSIG0002_933,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,189,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,934,PSIVISSIG0002_934,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,441,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,935,PSIVISSIG0002_935,41,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,504,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,936,PSIVISSIG0002_936,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,404,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,937,PSIVISSIG0002_937,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,45,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,938,PSIVISSIG0002_938,41,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,500,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,939,PSIVISSIG0002_939,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,717,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,940,PSIVISSIG0002_940,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,221,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,941,PSIVISSIG0002_941,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,346,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,942,PSIVISSIG0002_942,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,294,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,943,PSIVISSIG0002_943,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,209,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,944,PSIVISSIG0002_944,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,419,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,945,PSIVISSIG0002_945,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,320,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,946,PSIVISSIG0002_946,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,373,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,947,PSIVISSIG0002_947,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1406,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,948,PSIVISSIG0002_948,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,949,PSIVISSIG0002_949,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,763,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,950,PSIVISSIG0002_950,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,173,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,951,PSIVISSIG0002_951,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,693,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,952,PSIVISSIG0002_952,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,346,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,953,PSIVISSIG0002_953,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,130,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,954,PSIVISSIG0002_954,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1021,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,955,PSIVISSIG0002_955,47,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,203,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,956,PSIVISSIG0002_956,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1407,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,957,PSIVISSIG0002_957,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,903,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,958,PSIVISSIG0002_958,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,740,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,959,PSIVISSIG0002_959,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,632,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,960,PSIVISSIG0002_960,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1027,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,961,PSIVISSIG0002_961,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1171,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,962,PSIVISSIG0002_962,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,287,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,963,PSIVISSIG0002_963,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,846,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,964,PSIVISSIG0002_964,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,520,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,965,PSIVISSIG0002_965,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,431,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,966,PSIVISSIG0002_966,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,554,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,967,PSIVISSIG0002_967,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,751,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,968,PSIVISSIG0002_968,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1082,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,969,PSIVISSIG0002_969,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,516,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,970,PSIVISSIG0002_970,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,392,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,971,PSIVISSIG0002_971,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,573,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,972,PSIVISSIG0002_972,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,587,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,973,PSIVISSIG0002_973,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,460,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,974,PSIVISSIG0002_974,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,230,0,Death,NA,DEATH
PSIVISSIG0002,975,PSIVISSIG0002_975,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1250,0,Death,NA,DEATH
PSIVISSIG0002,976,PSIVISSIG0002_976,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,627,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,977,PSIVISSIG0002_977,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,466,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,978,PSIVISSIG0002_978,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,371,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,979,PSIVISSIG0002_979,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,407,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,980,PSIVISSIG0002_980,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,597,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,981,PSIVISSIG0002_981,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,739,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,982,PSIVISSIG0002_982,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1487,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,983,PSIVISSIG0002_983,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,322,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,984,PSIVISSIG0002_984,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,380,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,985,PSIVISSIG0002_985,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1311,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,986,PSIVISSIG0002_986,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,505,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,987,PSIVISSIG0002_987,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,336,0,Death,NA,DEATH
PSIVISSIG0002,988,PSIVISSIG0002_988,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,46,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,989,PSIVISSIG0002_989,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1460,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,990,PSIVISSIG0002_990,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1798,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,991,PSIVISSIG0002_991,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,903,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,992,PSIVISSIG0002_992,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,285,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,993,PSIVISSIG0002_993,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,19,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,994,PSIVISSIG0002_994,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,916,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,995,PSIVISSIG0002_995,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1307,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,996,PSIVISSIG0002_996,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1192,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,997,PSIVISSIG0002_997,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,854,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,998,PSIVISSIG0002_998,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,273,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,999,PSIVISSIG0002_999,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,162,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1000,PSIVISSIG0002_1000,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,859,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1001,PSIVISSIG0002_1001,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,475,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1002,PSIVISSIG0002_1002,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1303,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1003,PSIVISSIG0002_1003,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,298,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1004,PSIVISSIG0002_1004,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1000,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1005,PSIVISSIG0002_1005,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1420,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1006,PSIVISSIG0002_1006,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,284,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1007,PSIVISSIG0002_1007,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,980,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1008,PSIVISSIG0002_1008,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,808,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1009,PSIVISSIG0002_1009,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,985,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1010,PSIVISSIG0002_1010,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,136,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1011,PSIVISSIG0002_1011,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1012,PSIVISSIG0002_1012,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,285,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1013,PSIVISSIG0002_1013,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1014,PSIVISSIG0002_1014,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1078,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1015,PSIVISSIG0002_1015,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,856,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1016,PSIVISSIG0002_1016,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1078,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1017,PSIVISSIG0002_1017,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,243,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1018,PSIVISSIG0002_1018,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1397,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1019,PSIVISSIG0002_1019,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,62,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1020,PSIVISSIG0002_1020,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,115,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1021,PSIVISSIG0002_1021,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1022,PSIVISSIG0002_1022,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,859,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1023,PSIVISSIG0002_1023,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,231,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,1024,PSIVISSIG0002_1024,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,452,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1025,PSIVISSIG0002_1025,46,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,265,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1026,PSIVISSIG0002_1026,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,192,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1027,PSIVISSIG0002_1027,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,998,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1028,PSIVISSIG0002_1028,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,695,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1029,PSIVISSIG0002_1029,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1081,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1030,PSIVISSIG0002_1030,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1031,PSIVISSIG0002_1031,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,427,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1032,PSIVISSIG0002_1032,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,767,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1033,PSIVISSIG0002_1033,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,907,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1034,PSIVISSIG0002_1034,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1088,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1035,PSIVISSIG0002_1035,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,289,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1036,PSIVISSIG0002_1036,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,344,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1037,PSIVISSIG0002_1037,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,474,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1038,PSIVISSIG0002_1038,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,430,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1039,PSIVISSIG0002_1039,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,905,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1040,PSIVISSIG0002_1040,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,844,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1041,PSIVISSIG0002_1041,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1033,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1042,PSIVISSIG0002_1042,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,554,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1043,PSIVISSIG0002_1043,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,735,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1044,PSIVISSIG0002_1044,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,465,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1045,PSIVISSIG0002_1045,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,545,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1046,PSIVISSIG0002_1046,84,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,130,0,Death,NA,DEATH
PSIVISSIG0002,1047,PSIVISSIG0002_1047,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,86,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1048,PSIVISSIG0002_1048,57,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,581,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1049,PSIVISSIG0002_1049,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,229,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1050,PSIVISSIG0002_1050,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,996,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1051,PSIVISSIG0002_1051,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,765,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1052,PSIVISSIG0002_1052,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,381,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1053,PSIVISSIG0002_1053,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1067,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1054,PSIVISSIG0002_1054,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,676,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1055,PSIVISSIG0002_1055,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,192,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1056,PSIVISSIG0002_1056,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,175,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1057,PSIVISSIG0002_1057,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,732,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1058,PSIVISSIG0002_1058,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,738,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1059,PSIVISSIG0002_1059,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,860,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1060,PSIVISSIG0002_1060,69,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,289,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1061,PSIVISSIG0002_1061,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,578,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,1062,PSIVISSIG0002_1062,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1063,PSIVISSIG0002_1063,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,107,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1064,PSIVISSIG0002_1064,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1454,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1065,PSIVISSIG0002_1065,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,513,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1066,PSIVISSIG0002_1066,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,862,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1067,PSIVISSIG0002_1067,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,791,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1068,PSIVISSIG0002_1068,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,346,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1069,PSIVISSIG0002_1069,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,608,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1070,PSIVISSIG0002_1070,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,855,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1071,PSIVISSIG0002_1071,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,298,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1072,PSIVISSIG0002_1072,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,733,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1073,PSIVISSIG0002_1073,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1488,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1074,PSIVISSIG0002_1074,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1018,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1075,PSIVISSIG0002_1075,84,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,132,0,Death,NA,DEATH
PSIVISSIG0002,1076,PSIVISSIG0002_1076,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,814,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1077,PSIVISSIG0002_1077,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,559,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1078,PSIVISSIG0002_1078,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,302,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1079,PSIVISSIG0002_1079,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1721,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1080,PSIVISSIG0002_1080,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,774,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1081,PSIVISSIG0002_1081,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,562,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1082,PSIVISSIG0002_1082,58,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,397,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1083,PSIVISSIG0002_1083,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,800,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1084,PSIVISSIG0002_1084,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,41,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1085,PSIVISSIG0002_1085,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1026,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1086,PSIVISSIG0002_1086,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,369,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1087,PSIVISSIG0002_1087,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,415,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1088,PSIVISSIG0002_1088,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,399,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1089,PSIVISSIG0002_1089,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,137,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1090,PSIVISSIG0002_1090,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,254,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1091,PSIVISSIG0002_1091,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,588,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1092,PSIVISSIG0002_1092,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1307,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1093,PSIVISSIG0002_1093,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1364,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1094,PSIVISSIG0002_1094,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,189,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1095,PSIVISSIG0002_1095,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,534,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1096,PSIVISSIG0002_1096,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,859,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1097,PSIVISSIG0002_1097,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,583,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1098,PSIVISSIG0002_1098,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,587,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1099,PSIVISSIG0002_1099,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1071,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1100,PSIVISSIG0002_1100,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,680,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1101,PSIVISSIG0002_1101,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,511,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1102,PSIVISSIG0002_1102,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,250,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1103,PSIVISSIG0002_1103,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,833,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1104,PSIVISSIG0002_1104,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,172,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1105,PSIVISSIG0002_1105,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,346,0,Death,NA,DEATH
PSIVISSIG0002,1106,PSIVISSIG0002_1106,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,243,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1107,PSIVISSIG0002_1107,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,679,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1108,PSIVISSIG0002_1108,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,687,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1109,PSIVISSIG0002_1109,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,750,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1110,PSIVISSIG0002_1110,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1528,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1111,PSIVISSIG0002_1111,52,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,251,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1112,PSIVISSIG0002_1112,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,700,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1113,PSIVISSIG0002_1113,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,749,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1114,PSIVISSIG0002_1114,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,584,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,1115,PSIVISSIG0002_1115,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,972,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1116,PSIVISSIG0002_1116,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,784,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1117,PSIVISSIG0002_1117,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,127,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1118,PSIVISSIG0002_1118,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,449,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1119,PSIVISSIG0002_1119,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,243,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1120,PSIVISSIG0002_1120,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,115,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1121,PSIVISSIG0002_1121,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,858,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1122,PSIVISSIG0002_1122,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,355,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1123,PSIVISSIG0002_1123,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,531,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1124,PSIVISSIG0002_1124,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1054,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1125,PSIVISSIG0002_1125,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1048,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1126,PSIVISSIG0002_1126,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,558,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1127,PSIVISSIG0002_1127,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,643,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1128,PSIVISSIG0002_1128,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,383,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1129,PSIVISSIG0002_1129,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,315,0,PD,NA,DEATH
PSIVISSIG0002,1130,PSIVISSIG0002_1130,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,858,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1131,PSIVISSIG0002_1131,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,353,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1132,PSIVISSIG0002_1132,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,621,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1133,PSIVISSIG0002_1133,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,245,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1134,PSIVISSIG0002_1134,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1358,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1135,PSIVISSIG0002_1135,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,120,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1136,PSIVISSIG0002_1136,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,443,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1137,PSIVISSIG0002_1137,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,701,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1138,PSIVISSIG0002_1138,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,810,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1139,PSIVISSIG0002_1139,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1140,PSIVISSIG0002_1140,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1069,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1141,PSIVISSIG0002_1141,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1133,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1142,PSIVISSIG0002_1142,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1472,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1143,PSIVISSIG0002_1143,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1784,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1144,PSIVISSIG0002_1144,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,245,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1145,PSIVISSIG0002_1145,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,603,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1146,PSIVISSIG0002_1146,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,939,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,1147,PSIVISSIG0002_1147,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,586,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1148,PSIVISSIG0002_1148,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1195,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1149,PSIVISSIG0002_1149,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1150,PSIVISSIG0002_1150,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,565,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1151,PSIVISSIG0002_1151,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,67,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1152,PSIVISSIG0002_1152,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,192,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1153,PSIVISSIG0002_1153,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,136,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1154,PSIVISSIG0002_1154,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,849,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1155,PSIVISSIG0002_1155,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,560,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1156,PSIVISSIG0002_1156,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,659,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1157,PSIVISSIG0002_1157,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1314,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1158,PSIVISSIG0002_1158,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,270,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1159,PSIVISSIG0002_1159,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,270,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1160,PSIVISSIG0002_1160,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,851,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1161,PSIVISSIG0002_1161,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1078,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1162,PSIVISSIG0002_1162,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,646,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1163,PSIVISSIG0002_1163,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,402,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1164,PSIVISSIG0002_1164,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,719,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1165,PSIVISSIG0002_1165,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,264,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1166,PSIVISSIG0002_1166,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1803,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1167,PSIVISSIG0002_1167,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,711,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1168,PSIVISSIG0002_1168,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,624,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1169,PSIVISSIG0002_1169,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,885,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1170,PSIVISSIG0002_1170,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,196,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1171,PSIVISSIG0002_1171,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,380,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1172,PSIVISSIG0002_1172,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,76,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1173,PSIVISSIG0002_1173,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,615,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1174,PSIVISSIG0002_1174,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,609,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1175,PSIVISSIG0002_1175,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,477,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1176,PSIVISSIG0002_1176,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,877,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1177,PSIVISSIG0002_1177,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1032,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1178,PSIVISSIG0002_1178,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,765,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1179,PSIVISSIG0002_1179,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,787,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1180,PSIVISSIG0002_1180,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,237,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1181,PSIVISSIG0002_1181,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,172,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1182,PSIVISSIG0002_1182,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1516,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1183,PSIVISSIG0002_1183,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1546,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1184,PSIVISSIG0002_1184,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,710,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1185,PSIVISSIG0002_1185,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,299,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1186,PSIVISSIG0002_1186,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1522,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1187,PSIVISSIG0002_1187,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1363,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1188,PSIVISSIG0002_1188,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,499,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1189,PSIVISSIG0002_1189,64,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1322,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1190,PSIVISSIG0002_1190,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1086,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1191,PSIVISSIG0002_1191,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,792,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1192,PSIVISSIG0002_1192,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,976,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1193,PSIVISSIG0002_1193,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,294,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1194,PSIVISSIG0002_1194,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,188,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1195,PSIVISSIG0002_1195,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1001,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1196,PSIVISSIG0002_1196,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,353,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1197,PSIVISSIG0002_1197,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,552,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1198,PSIVISSIG0002_1198,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,799,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1199,PSIVISSIG0002_1199,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,519,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1200,PSIVISSIG0002_1200,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,259,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1201,PSIVISSIG0002_1201,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,357,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1202,PSIVISSIG0002_1202,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,648,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1203,PSIVISSIG0002_1203,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1476,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1204,PSIVISSIG0002_1204,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,972,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1205,PSIVISSIG0002_1205,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1158,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1206,PSIVISSIG0002_1206,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,428,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1207,PSIVISSIG0002_1207,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,447,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1208,PSIVISSIG0002_1208,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,679,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1209,PSIVISSIG0002_1209,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,215,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1210,PSIVISSIG0002_1210,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1131,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1211,PSIVISSIG0002_1211,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1325,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1212,PSIVISSIG0002_1212,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,762,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1213,PSIVISSIG0002_1213,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,118,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1214,PSIVISSIG0002_1214,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,788,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1215,PSIVISSIG0002_1215,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,608,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1216,PSIVISSIG0002_1216,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1217,PSIVISSIG0002_1217,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,536,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1218,PSIVISSIG0002_1218,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,348,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1219,PSIVISSIG0002_1219,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,780,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1220,PSIVISSIG0002_1220,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1221,PSIVISSIG0002_1221,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,41,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1222,PSIVISSIG0002_1222,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,550,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1223,PSIVISSIG0002_1223,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,37,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1224,PSIVISSIG0002_1224,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,797,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1225,PSIVISSIG0002_1225,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,652,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1226,PSIVISSIG0002_1226,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,471,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1227,PSIVISSIG0002_1227,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1136,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1228,PSIVISSIG0002_1228,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,807,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1229,PSIVISSIG0002_1229,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,475,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1230,PSIVISSIG0002_1230,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,290,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1231,PSIVISSIG0002_1231,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,302,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1232,PSIVISSIG0002_1232,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,431,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1233,PSIVISSIG0002_1233,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,76,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1234,PSIVISSIG0002_1234,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,423,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1235,PSIVISSIG0002_1235,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,636,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1236,PSIVISSIG0002_1236,58,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,396,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1237,PSIVISSIG0002_1237,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,587,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1238,PSIVISSIG0002_1238,61,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,596,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1239,PSIVISSIG0002_1239,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,185,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1240,PSIVISSIG0002_1240,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,306,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1241,PSIVISSIG0002_1241,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,789,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1242,PSIVISSIG0002_1242,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,720,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1243,PSIVISSIG0002_1243,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,704,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1244,PSIVISSIG0002_1244,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,117,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1245,PSIVISSIG0002_1245,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,747,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1246,PSIVISSIG0002_1246,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,741,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1247,PSIVISSIG0002_1247,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,748,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1248,PSIVISSIG0002_1248,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1194,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1249,PSIVISSIG0002_1249,47,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,1250,PSIVISSIG0002_1250,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1408,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1251,PSIVISSIG0002_1251,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,672,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1252,PSIVISSIG0002_1252,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,520,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1253,PSIVISSIG0002_1253,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,439,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1254,PSIVISSIG0002_1254,69,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,577,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1255,PSIVISSIG0002_1255,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,483,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1256,PSIVISSIG0002_1256,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,455,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1257,PSIVISSIG0002_1257,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,394,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1258,PSIVISSIG0002_1258,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1259,PSIVISSIG0002_1259,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,458,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1260,PSIVISSIG0002_1260,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,589,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1261,PSIVISSIG0002_1261,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,228,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1262,PSIVISSIG0002_1262,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,699,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1263,PSIVISSIG0002_1263,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1409,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1264,PSIVISSIG0002_1264,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,397,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1265,PSIVISSIG0002_1265,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,415,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1266,PSIVISSIG0002_1266,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,578,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1267,PSIVISSIG0002_1267,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,746,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1268,PSIVISSIG0002_1268,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,736,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1269,PSIVISSIG0002_1269,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,766,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1270,PSIVISSIG0002_1270,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,261,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1271,PSIVISSIG0002_1271,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,304,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1272,PSIVISSIG0002_1272,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1021,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1273,PSIVISSIG0002_1273,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1247,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1274,PSIVISSIG0002_1274,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,740,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1275,PSIVISSIG0002_1275,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,411,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1276,PSIVISSIG0002_1276,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,740,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1277,PSIVISSIG0002_1277,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,128,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,1278,PSIVISSIG0002_1278,64,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1321,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1279,PSIVISSIG0002_1279,84,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,141,0,Death,NA,DEATH
PSIVISSIG0002,1280,PSIVISSIG0002_1280,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,586,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1281,PSIVISSIG0002_1281,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,737,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1282,PSIVISSIG0002_1282,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,639,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1283,PSIVISSIG0002_1283,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1182,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1284,PSIVISSIG0002_1284,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1508,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1285,PSIVISSIG0002_1285,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,446,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1286,PSIVISSIG0002_1286,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,812,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1287,PSIVISSIG0002_1287,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,417,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1288,PSIVISSIG0002_1288,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,812,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1289,PSIVISSIG0002_1289,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1083,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1290,PSIVISSIG0002_1290,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,667,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1291,PSIVISSIG0002_1291,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,803,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1292,PSIVISSIG0002_1292,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,314,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1293,PSIVISSIG0002_1293,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1587,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1294,PSIVISSIG0002_1294,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,136,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1295,PSIVISSIG0002_1295,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1074,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1296,PSIVISSIG0002_1296,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1397,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1297,PSIVISSIG0002_1297,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,841,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1298,PSIVISSIG0002_1298,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1068,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1299,PSIVISSIG0002_1299,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,233,0,Death,NA,DEATH
PSIVISSIG0002,1300,PSIVISSIG0002_1300,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1355,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1301,PSIVISSIG0002_1301,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,905,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1302,PSIVISSIG0002_1302,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1709,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1303,PSIVISSIG0002_1303,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,238,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1304,PSIVISSIG0002_1304,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,547,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1305,PSIVISSIG0002_1305,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1302,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1306,PSIVISSIG0002_1306,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,511,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1307,PSIVISSIG0002_1307,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,318,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1308,PSIVISSIG0002_1308,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1414,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1309,PSIVISSIG0002_1309,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1295,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1310,PSIVISSIG0002_1310,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,575,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1311,PSIVISSIG0002_1311,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,695,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1312,PSIVISSIG0002_1312,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,845,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1313,PSIVISSIG0002_1313,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,396,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1314,PSIVISSIG0002_1314,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1086,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1315,PSIVISSIG0002_1315,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,713,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1316,PSIVISSIG0002_1316,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,807,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1317,PSIVISSIG0002_1317,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1545,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1318,PSIVISSIG0002_1318,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,398,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1319,PSIVISSIG0002_1319,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,655,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1320,PSIVISSIG0002_1320,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1208,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1321,PSIVISSIG0002_1321,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1941,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1322,PSIVISSIG0002_1322,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1323,PSIVISSIG0002_1323,70,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,424,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1324,PSIVISSIG0002_1324,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,512,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1325,PSIVISSIG0002_1325,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,314,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1326,PSIVISSIG0002_1326,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,507,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1327,PSIVISSIG0002_1327,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,809,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1328,PSIVISSIG0002_1328,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,734,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1329,PSIVISSIG0002_1329,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,796,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1330,PSIVISSIG0002_1330,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,850,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1331,PSIVISSIG0002_1331,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,915,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1332,PSIVISSIG0002_1332,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,533,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1333,PSIVISSIG0002_1333,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1471,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1334,PSIVISSIG0002_1334,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,150,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1335,PSIVISSIG0002_1335,70,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,424,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1336,PSIVISSIG0002_1336,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,696,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1337,PSIVISSIG0002_1337,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1471,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1338,PSIVISSIG0002_1338,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1055,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1339,PSIVISSIG0002_1339,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1654,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1340,PSIVISSIG0002_1340,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,986,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1341,PSIVISSIG0002_1341,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,523,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1342,PSIVISSIG0002_1342,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,358,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1343,PSIVISSIG0002_1343,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,566,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1344,PSIVISSIG0002_1344,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,629,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1345,PSIVISSIG0002_1345,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1049,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1346,PSIVISSIG0002_1346,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1468,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1347,PSIVISSIG0002_1347,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,605,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1348,PSIVISSIG0002_1348,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1220,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1349,PSIVISSIG0002_1349,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,470,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1350,PSIVISSIG0002_1350,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,436,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1351,PSIVISSIG0002_1351,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,176,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1352,PSIVISSIG0002_1352,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,228,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1353,PSIVISSIG0002_1353,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,734,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1354,PSIVISSIG0002_1354,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,556,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1355,PSIVISSIG0002_1355,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,161,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1356,PSIVISSIG0002_1356,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,636,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1357,PSIVISSIG0002_1357,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1358,PSIVISSIG0002_1358,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1359,PSIVISSIG0002_1359,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,146,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1360,PSIVISSIG0002_1360,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,943,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1361,PSIVISSIG0002_1361,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,829,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1362,PSIVISSIG0002_1362,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,900,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1363,PSIVISSIG0002_1363,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,189,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1364,PSIVISSIG0002_1364,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,541,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1365,PSIVISSIG0002_1365,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,468,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1366,PSIVISSIG0002_1366,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1391,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1367,PSIVISSIG0002_1367,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,298,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1368,PSIVISSIG0002_1368,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,280,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1369,PSIVISSIG0002_1369,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1370,PSIVISSIG0002_1370,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1131,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1371,PSIVISSIG0002_1371,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1083,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1372,PSIVISSIG0002_1372,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,636,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1373,PSIVISSIG0002_1373,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,244,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1374,PSIVISSIG0002_1374,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,313,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1375,PSIVISSIG0002_1375,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,498,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1376,PSIVISSIG0002_1376,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,405,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1377,PSIVISSIG0002_1377,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1307,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1378,PSIVISSIG0002_1378,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,257,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1379,PSIVISSIG0002_1379,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,385,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1380,PSIVISSIG0002_1380,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,282,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1381,PSIVISSIG0002_1381,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,967,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1382,PSIVISSIG0002_1382,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,583,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1383,PSIVISSIG0002_1383,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1812,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1384,PSIVISSIG0002_1384,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1079,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1385,PSIVISSIG0002_1385,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,193,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1386,PSIVISSIG0002_1386,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,687,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1387,PSIVISSIG0002_1387,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,136,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1388,PSIVISSIG0002_1388,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,754,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1389,PSIVISSIG0002_1389,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1303,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1390,PSIVISSIG0002_1390,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,301,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1391,PSIVISSIG0002_1391,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1657,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1392,PSIVISSIG0002_1392,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,490,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1393,PSIVISSIG0002_1393,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,519,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1394,PSIVISSIG0002_1394,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,768,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1395,PSIVISSIG0002_1395,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,733,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1396,PSIVISSIG0002_1396,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,72,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1397,PSIVISSIG0002_1397,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,575,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1398,PSIVISSIG0002_1398,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,717,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1399,PSIVISSIG0002_1399,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,458,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1400,PSIVISSIG0002_1400,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,405,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1401,PSIVISSIG0002_1401,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1081,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1402,PSIVISSIG0002_1402,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,788,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1403,PSIVISSIG0002_1403,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1086,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1404,PSIVISSIG0002_1404,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,471,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1405,PSIVISSIG0002_1405,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,751,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1406,PSIVISSIG0002_1406,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,411,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1407,PSIVISSIG0002_1407,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1257,0,Death,NA,DEATH
PSIVISSIG0002,1408,PSIVISSIG0002_1408,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1083,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1409,PSIVISSIG0002_1409,46,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,256,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1410,PSIVISSIG0002_1410,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1303,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1411,PSIVISSIG0002_1411,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,33,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1412,PSIVISSIG0002_1412,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1077,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1413,PSIVISSIG0002_1413,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1013,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1414,PSIVISSIG0002_1414,47,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,196,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,1415,PSIVISSIG0002_1415,37,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,615,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1416,PSIVISSIG0002_1416,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1166,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1417,PSIVISSIG0002_1417,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,716,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1418,PSIVISSIG0002_1418,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,39,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1419,PSIVISSIG0002_1419,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,39,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1420,PSIVISSIG0002_1420,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1080,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1421,PSIVISSIG0002_1421,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,175,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1422,PSIVISSIG0002_1422,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,127,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1423,PSIVISSIG0002_1423,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,335,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1424,PSIVISSIG0002_1424,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,704,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1425,PSIVISSIG0002_1425,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1079,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1426,PSIVISSIG0002_1426,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,240,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1427,PSIVISSIG0002_1427,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,156,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,1428,PSIVISSIG0002_1428,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1696,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1429,PSIVISSIG0002_1429,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,514,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1430,PSIVISSIG0002_1430,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,634,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1431,PSIVISSIG0002_1431,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,944,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1432,PSIVISSIG0002_1432,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,372,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1433,PSIVISSIG0002_1433,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,761,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1434,PSIVISSIG0002_1434,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1435,PSIVISSIG0002_1435,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,65,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1436,PSIVISSIG0002_1436,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1929,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1437,PSIVISSIG0002_1437,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,574,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1438,PSIVISSIG0002_1438,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,872,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1439,PSIVISSIG0002_1439,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,388,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1440,PSIVISSIG0002_1440,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1090,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1441,PSIVISSIG0002_1441,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1184,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1442,PSIVISSIG0002_1442,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,236,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1443,PSIVISSIG0002_1443,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,160,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1444,PSIVISSIG0002_1444,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,800,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1445,PSIVISSIG0002_1445,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1681,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1446,PSIVISSIG0002_1446,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1345,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1447,PSIVISSIG0002_1447,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,178,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1448,PSIVISSIG0002_1448,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1474,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1449,PSIVISSIG0002_1449,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,679,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1450,PSIVISSIG0002_1450,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,247,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1451,PSIVISSIG0002_1451,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,634,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1452,PSIVISSIG0002_1452,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1024,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1453,PSIVISSIG0002_1453,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,787,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1454,PSIVISSIG0002_1454,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1135,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1455,PSIVISSIG0002_1455,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,588,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1456,PSIVISSIG0002_1456,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,536,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1457,PSIVISSIG0002_1457,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,324,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1458,PSIVISSIG0002_1458,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,473,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1459,PSIVISSIG0002_1459,71,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1460,PSIVISSIG0002_1460,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,457,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1461,PSIVISSIG0002_1461,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1292,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1462,PSIVISSIG0002_1462,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1071,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1463,PSIVISSIG0002_1463,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,437,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1464,PSIVISSIG0002_1464,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,375,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1465,PSIVISSIG0002_1465,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,543,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1466,PSIVISSIG0002_1466,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,662,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1467,PSIVISSIG0002_1467,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,366,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1468,PSIVISSIG0002_1468,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,231,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1469,PSIVISSIG0002_1469,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1350,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1470,PSIVISSIG0002_1470,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,473,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1471,PSIVISSIG0002_1471,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1154,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1472,PSIVISSIG0002_1472,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1161,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1473,PSIVISSIG0002_1473,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1221,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1474,PSIVISSIG0002_1474,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1697,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1475,PSIVISSIG0002_1475,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1291,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1476,PSIVISSIG0002_1476,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1408,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1477,PSIVISSIG0002_1477,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,888,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1478,PSIVISSIG0002_1478,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1512,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1479,PSIVISSIG0002_1479,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,303,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1480,PSIVISSIG0002_1480,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,298,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1481,PSIVISSIG0002_1481,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,515,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1482,PSIVISSIG0002_1482,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,568,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1483,PSIVISSIG0002_1483,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1034,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1484,PSIVISSIG0002_1484,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,942,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1485,PSIVISSIG0002_1485,64,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1312,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1486,PSIVISSIG0002_1486,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1590,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1487,PSIVISSIG0002_1487,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,456,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1488,PSIVISSIG0002_1488,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1803,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1489,PSIVISSIG0002_1489,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1421,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1490,PSIVISSIG0002_1490,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,176,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1491,PSIVISSIG0002_1491,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1398,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1492,PSIVISSIG0002_1492,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,563,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1493,PSIVISSIG0002_1493,72,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,735,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1494,PSIVISSIG0002_1494,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1130,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1495,PSIVISSIG0002_1495,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,757,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1496,PSIVISSIG0002_1496,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,116,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1497,PSIVISSIG0002_1497,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,304,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1498,PSIVISSIG0002_1498,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,607,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1499,PSIVISSIG0002_1499,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1500,PSIVISSIG0002_1500,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,446,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1501,PSIVISSIG0002_1501,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,975,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1502,PSIVISSIG0002_1502,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,938,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1503,PSIVISSIG0002_1503,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,590,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1504,PSIVISSIG0002_1504,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,116,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1505,PSIVISSIG0002_1505,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,353,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1506,PSIVISSIG0002_1506,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,566,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1507,PSIVISSIG0002_1507,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1452,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1508,PSIVISSIG0002_1508,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1509,PSIVISSIG0002_1509,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,856,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1510,PSIVISSIG0002_1510,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,197,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1511,PSIVISSIG0002_1511,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,659,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1512,PSIVISSIG0002_1512,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1063,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1513,PSIVISSIG0002_1513,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,272,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1514,PSIVISSIG0002_1514,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,662,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1515,PSIVISSIG0002_1515,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,983,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1516,PSIVISSIG0002_1516,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,676,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1517,PSIVISSIG0002_1517,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,481,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1518,PSIVISSIG0002_1518,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,886,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1519,PSIVISSIG0002_1519,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,526,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1520,PSIVISSIG0002_1520,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,352,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1521,PSIVISSIG0002_1521,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1138,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1522,PSIVISSIG0002_1522,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1523,PSIVISSIG0002_1523,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1722,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1524,PSIVISSIG0002_1524,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,1525,PSIVISSIG0002_1525,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1739,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1526,PSIVISSIG0002_1526,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1527,PSIVISSIG0002_1527,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,96,0,Death,NA,DEATH
PSIVISSIG0002,1528,PSIVISSIG0002_1528,72,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,730,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1529,PSIVISSIG0002_1529,62,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,452,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1530,PSIVISSIG0002_1530,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1484,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1531,PSIVISSIG0002_1531,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1171,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1532,PSIVISSIG0002_1532,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1494,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1533,PSIVISSIG0002_1533,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,242,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1534,PSIVISSIG0002_1534,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,177,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1535,PSIVISSIG0002_1535,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,843,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1536,PSIVISSIG0002_1536,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,606,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1537,PSIVISSIG0002_1537,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,888,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1538,PSIVISSIG0002_1538,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,389,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1539,PSIVISSIG0002_1539,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,131,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1540,PSIVISSIG0002_1540,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,425,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1541,PSIVISSIG0002_1541,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,195,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1542,PSIVISSIG0002_1542,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,452,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1543,PSIVISSIG0002_1543,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,493,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1544,PSIVISSIG0002_1544,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,237,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1545,PSIVISSIG0002_1545,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1473,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1546,PSIVISSIG0002_1546,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,741,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1547,PSIVISSIG0002_1547,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,413,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1548,PSIVISSIG0002_1548,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1012,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1549,PSIVISSIG0002_1549,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,467,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1550,PSIVISSIG0002_1550,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,279,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1551,PSIVISSIG0002_1551,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,287,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1552,PSIVISSIG0002_1552,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1405,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1553,PSIVISSIG0002_1553,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1180,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1554,PSIVISSIG0002_1554,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,663,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1555,PSIVISSIG0002_1555,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,369,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1556,PSIVISSIG0002_1556,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,267,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1557,PSIVISSIG0002_1557,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,344,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1558,PSIVISSIG0002_1558,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,190,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1559,PSIVISSIG0002_1559,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,801,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1560,PSIVISSIG0002_1560,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,118,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1561,PSIVISSIG0002_1561,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,861,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1562,PSIVISSIG0002_1562,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,696,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1563,PSIVISSIG0002_1563,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,509,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1564,PSIVISSIG0002_1564,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1565,PSIVISSIG0002_1565,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,277,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1566,PSIVISSIG0002_1566,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1328,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1567,PSIVISSIG0002_1567,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,463,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1568,PSIVISSIG0002_1568,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1283,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1569,PSIVISSIG0002_1569,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,620,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1570,PSIVISSIG0002_1570,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1352,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1571,PSIVISSIG0002_1571,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,850,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1572,PSIVISSIG0002_1572,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,387,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1573,PSIVISSIG0002_1573,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,593,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1574,PSIVISSIG0002_1574,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,746,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1575,PSIVISSIG0002_1575,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,45,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1576,PSIVISSIG0002_1576,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,555,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1577,PSIVISSIG0002_1577,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,386,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1578,PSIVISSIG0002_1578,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,461,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1579,PSIVISSIG0002_1579,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,396,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1580,PSIVISSIG0002_1580,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,548,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1581,PSIVISSIG0002_1581,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,819,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1582,PSIVISSIG0002_1582,45,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,248,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1583,PSIVISSIG0002_1583,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,983,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1584,PSIVISSIG0002_1584,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1050,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1585,PSIVISSIG0002_1585,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,249,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1586,PSIVISSIG0002_1586,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,865,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1587,PSIVISSIG0002_1587,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,63,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1588,PSIVISSIG0002_1588,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,121,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1589,PSIVISSIG0002_1589,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,280,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1590,PSIVISSIG0002_1590,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1171,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1591,PSIVISSIG0002_1591,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,658,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1592,PSIVISSIG0002_1592,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1001,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1593,PSIVISSIG0002_1593,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,941,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1594,PSIVISSIG0002_1594,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,131,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1595,PSIVISSIG0002_1595,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1191,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1596,PSIVISSIG0002_1596,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1237,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1597,PSIVISSIG0002_1597,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,694,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1598,PSIVISSIG0002_1598,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,742,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1599,PSIVISSIG0002_1599,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,657,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1600,PSIVISSIG0002_1600,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,582,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1601,PSIVISSIG0002_1601,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1328,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1602,PSIVISSIG0002_1602,84,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,147,0,Death,NA,DEATH
PSIVISSIG0002,1603,PSIVISSIG0002_1603,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1045,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1604,PSIVISSIG0002_1604,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,350,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1605,PSIVISSIG0002_1605,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,621,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1606,PSIVISSIG0002_1606,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1915,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1607,PSIVISSIG0002_1607,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,474,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1608,PSIVISSIG0002_1608,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,225,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1609,PSIVISSIG0002_1609,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1087,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1610,PSIVISSIG0002_1610,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,909,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1611,PSIVISSIG0002_1611,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,237,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1612,PSIVISSIG0002_1612,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,541,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1613,PSIVISSIG0002_1613,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,633,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1614,PSIVISSIG0002_1614,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,478,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1615,PSIVISSIG0002_1615,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,806,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1616,PSIVISSIG0002_1616,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1079,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1617,PSIVISSIG0002_1617,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,688,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1618,PSIVISSIG0002_1618,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,850,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1619,PSIVISSIG0002_1619,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,571,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1620,PSIVISSIG0002_1620,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,763,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1621,PSIVISSIG0002_1621,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,355,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1622,PSIVISSIG0002_1622,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,340,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1623,PSIVISSIG0002_1623,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1135,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1624,PSIVISSIG0002_1624,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,866,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1625,PSIVISSIG0002_1625,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,462,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1626,PSIVISSIG0002_1626,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,239,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1627,PSIVISSIG0002_1627,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1812,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1628,PSIVISSIG0002_1628,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,852,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1629,PSIVISSIG0002_1629,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,288,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1630,PSIVISSIG0002_1630,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,523,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1631,PSIVISSIG0002_1631,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1817,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1632,PSIVISSIG0002_1632,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,327,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1633,PSIVISSIG0002_1633,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,198,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1634,PSIVISSIG0002_1634,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,627,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1635,PSIVISSIG0002_1635,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,311,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1636,PSIVISSIG0002_1636,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,759,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1637,PSIVISSIG0002_1637,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,428,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1638,PSIVISSIG0002_1638,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,499,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1639,PSIVISSIG0002_1639,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1005,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1640,PSIVISSIG0002_1640,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,540,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1641,PSIVISSIG0002_1641,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,752,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1642,PSIVISSIG0002_1642,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,307,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1643,PSIVISSIG0002_1643,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1193,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1644,PSIVISSIG0002_1644,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,574,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1645,PSIVISSIG0002_1645,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,514,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1646,PSIVISSIG0002_1646,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,539,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1647,PSIVISSIG0002_1647,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,140,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1648,PSIVISSIG0002_1648,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,579,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1649,PSIVISSIG0002_1649,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,291,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1650,PSIVISSIG0002_1650,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,972,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1651,PSIVISSIG0002_1651,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,195,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1652,PSIVISSIG0002_1652,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1094,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1653,PSIVISSIG0002_1653,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,612,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1654,PSIVISSIG0002_1654,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1478,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1655,PSIVISSIG0002_1655,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,807,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1656,PSIVISSIG0002_1656,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,165,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1657,PSIVISSIG0002_1657,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,484,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1658,PSIVISSIG0002_1658,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1309,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1659,PSIVISSIG0002_1659,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,469,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1660,PSIVISSIG0002_1660,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,661,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1661,PSIVISSIG0002_1661,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,484,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1662,PSIVISSIG0002_1662,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,746,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1663,PSIVISSIG0002_1663,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,590,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1664,PSIVISSIG0002_1664,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,160,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1665,PSIVISSIG0002_1665,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,317,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1666,PSIVISSIG0002_1666,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1508,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1667,PSIVISSIG0002_1667,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1668,PSIVISSIG0002_1668,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,230,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1669,PSIVISSIG0002_1669,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,588,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1670,PSIVISSIG0002_1670,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,142,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1671,PSIVISSIG0002_1671,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,635,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1672,PSIVISSIG0002_1672,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,410,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1673,PSIVISSIG0002_1673,62,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,466,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1674,PSIVISSIG0002_1674,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,462,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1675,PSIVISSIG0002_1675,67,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,918,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1676,PSIVISSIG0002_1676,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,448,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1677,PSIVISSIG0002_1677,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,230,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1678,PSIVISSIG0002_1678,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,559,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1679,PSIVISSIG0002_1679,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,634,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1680,PSIVISSIG0002_1680,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,256,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1681,PSIVISSIG0002_1681,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,590,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1682,PSIVISSIG0002_1682,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1362,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1683,PSIVISSIG0002_1683,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,561,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1684,PSIVISSIG0002_1684,73,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,714,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1685,PSIVISSIG0002_1685,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,296,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1686,PSIVISSIG0002_1686,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,353,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1687,PSIVISSIG0002_1687,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1063,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1688,PSIVISSIG0002_1688,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,171,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1689,PSIVISSIG0002_1689,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,244,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1690,PSIVISSIG0002_1690,61,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,597,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1691,PSIVISSIG0002_1691,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,834,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1692,PSIVISSIG0002_1692,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,26,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1693,PSIVISSIG0002_1693,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,785,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1694,PSIVISSIG0002_1694,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,982,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1695,PSIVISSIG0002_1695,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,55,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1696,PSIVISSIG0002_1696,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,576,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,1697,PSIVISSIG0002_1697,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1442,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1698,PSIVISSIG0002_1698,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,572,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1699,PSIVISSIG0002_1699,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,895,0,Death,NA,DEATH
PSIVISSIG0002,1700,PSIVISSIG0002_1700,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,233,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1701,PSIVISSIG0002_1701,48,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1032,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1702,PSIVISSIG0002_1702,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,479,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1703,PSIVISSIG0002_1703,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,771,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1704,PSIVISSIG0002_1704,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,557,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1705,PSIVISSIG0002_1705,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1809,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1706,PSIVISSIG0002_1706,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,675,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1707,PSIVISSIG0002_1707,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,980,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1708,PSIVISSIG0002_1708,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,986,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1709,PSIVISSIG0002_1709,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,261,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1710,PSIVISSIG0002_1710,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,607,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1711,PSIVISSIG0002_1711,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1155,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1712,PSIVISSIG0002_1712,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1725,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1713,PSIVISSIG0002_1713,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,619,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1714,PSIVISSIG0002_1714,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,523,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1715,PSIVISSIG0002_1715,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,983,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1716,PSIVISSIG0002_1716,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,619,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1717,PSIVISSIG0002_1717,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1931,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1718,PSIVISSIG0002_1718,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1019,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1719,PSIVISSIG0002_1719,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,28,0,Death,NA,DEATH
PSIVISSIG0002,1720,PSIVISSIG0002_1720,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,848,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1721,PSIVISSIG0002_1721,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,422,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1722,PSIVISSIG0002_1722,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,490,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1723,PSIVISSIG0002_1723,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,380,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1724,PSIVISSIG0002_1724,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1157,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1725,PSIVISSIG0002_1725,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,444,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1726,PSIVISSIG0002_1726,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1370,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1727,PSIVISSIG0002_1727,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1884,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1728,PSIVISSIG0002_1728,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1395,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1729,PSIVISSIG0002_1729,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,390,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1730,PSIVISSIG0002_1730,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,507,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1731,PSIVISSIG0002_1731,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,631,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1732,PSIVISSIG0002_1732,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,413,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1733,PSIVISSIG0002_1733,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1130,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1734,PSIVISSIG0002_1734,58,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,412,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1735,PSIVISSIG0002_1735,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1362,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1736,PSIVISSIG0002_1736,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,770,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1737,PSIVISSIG0002_1737,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,549,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1738,PSIVISSIG0002_1738,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,319,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1739,PSIVISSIG0002_1739,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,792,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1740,PSIVISSIG0002_1740,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,664,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1741,PSIVISSIG0002_1741,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,692,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1742,PSIVISSIG0002_1742,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,790,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1743,PSIVISSIG0002_1743,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,29,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1744,PSIVISSIG0002_1744,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,346,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1745,PSIVISSIG0002_1745,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,75,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1746,PSIVISSIG0002_1746,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1747,PSIVISSIG0002_1747,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,456,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1748,PSIVISSIG0002_1748,37,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,611,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1749,PSIVISSIG0002_1749,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,851,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1750,PSIVISSIG0002_1750,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,419,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1751,PSIVISSIG0002_1751,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,866,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1752,PSIVISSIG0002_1752,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,708,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1753,PSIVISSIG0002_1753,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1345,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1754,PSIVISSIG0002_1754,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,712,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1755,PSIVISSIG0002_1755,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,37,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1756,PSIVISSIG0002_1756,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,799,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1757,PSIVISSIG0002_1757,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1002,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1758,PSIVISSIG0002_1758,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,975,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1759,PSIVISSIG0002_1759,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,856,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1760,PSIVISSIG0002_1760,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,798,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1761,PSIVISSIG0002_1761,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,375,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1762,PSIVISSIG0002_1762,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1726,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1763,PSIVISSIG0002_1763,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,313,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1764,PSIVISSIG0002_1764,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,786,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1765,PSIVISSIG0002_1765,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,857,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1766,PSIVISSIG0002_1766,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,426,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1767,PSIVISSIG0002_1767,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,752,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1768,PSIVISSIG0002_1768,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,902,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1769,PSIVISSIG0002_1769,45,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1770,PSIVISSIG0002_1770,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,413,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1771,PSIVISSIG0002_1771,48,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1049,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1772,PSIVISSIG0002_1772,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,467,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1773,PSIVISSIG0002_1773,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,614,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1774,PSIVISSIG0002_1774,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,44,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1775,PSIVISSIG0002_1775,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,354,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1776,PSIVISSIG0002_1776,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,470,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1777,PSIVISSIG0002_1777,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,339,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1778,PSIVISSIG0002_1778,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1403,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1779,PSIVISSIG0002_1779,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,217,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1780,PSIVISSIG0002_1780,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,128,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1781,PSIVISSIG0002_1781,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,605,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1782,PSIVISSIG0002_1782,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,479,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1783,PSIVISSIG0002_1783,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,353,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1784,PSIVISSIG0002_1784,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,407,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1785,PSIVISSIG0002_1785,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,630,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1786,PSIVISSIG0002_1786,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,737,0,Death,NA,DEATH
PSIVISSIG0002,1787,PSIVISSIG0002_1787,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,749,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1788,PSIVISSIG0002_1788,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,734,0,Death,NA,DEATH
PSIVISSIG0002,1789,PSIVISSIG0002_1789,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,398,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1790,PSIVISSIG0002_1790,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1791,PSIVISSIG0002_1791,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,397,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1792,PSIVISSIG0002_1792,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,673,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1793,PSIVISSIG0002_1793,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,401,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1794,PSIVISSIG0002_1794,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,292,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1795,PSIVISSIG0002_1795,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1097,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1796,PSIVISSIG0002_1796,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,438,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1797,PSIVISSIG0002_1797,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1476,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1798,PSIVISSIG0002_1798,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,186,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1799,PSIVISSIG0002_1799,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,831,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1800,PSIVISSIG0002_1800,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1039,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1801,PSIVISSIG0002_1801,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1302,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1802,PSIVISSIG0002_1802,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1448,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1803,PSIVISSIG0002_1803,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1006,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1804,PSIVISSIG0002_1804,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,582,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1805,PSIVISSIG0002_1805,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1654,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1806,PSIVISSIG0002_1806,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1318,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1807,PSIVISSIG0002_1807,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,623,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1808,PSIVISSIG0002_1808,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,460,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1809,PSIVISSIG0002_1809,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,636,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1810,PSIVISSIG0002_1810,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,342,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1811,PSIVISSIG0002_1811,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,153,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1812,PSIVISSIG0002_1812,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,238,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1813,PSIVISSIG0002_1813,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1209,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1814,PSIVISSIG0002_1814,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,623,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1815,PSIVISSIG0002_1815,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1928,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1816,PSIVISSIG0002_1816,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,709,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1817,PSIVISSIG0002_1817,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1296,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1818,PSIVISSIG0002_1818,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,207,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1819,PSIVISSIG0002_1819,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,356,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1820,PSIVISSIG0002_1820,56,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,213,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1821,PSIVISSIG0002_1821,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,848,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1822,PSIVISSIG0002_1822,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1479,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1823,PSIVISSIG0002_1823,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,344,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1824,PSIVISSIG0002_1824,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1825,PSIVISSIG0002_1825,69,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,283,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1826,PSIVISSIG0002_1826,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1827,PSIVISSIG0002_1827,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1358,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1828,PSIVISSIG0002_1828,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,436,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1829,PSIVISSIG0002_1829,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,750,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1830,PSIVISSIG0002_1830,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,615,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1831,PSIVISSIG0002_1831,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,709,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1832,PSIVISSIG0002_1832,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1659,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1833,PSIVISSIG0002_1833,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1470,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1834,PSIVISSIG0002_1834,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,777,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1835,PSIVISSIG0002_1835,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1307,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1836,PSIVISSIG0002_1836,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,574,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1837,PSIVISSIG0002_1837,41,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,510,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1838,PSIVISSIG0002_1838,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1839,PSIVISSIG0002_1839,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,574,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1840,PSIVISSIG0002_1840,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1314,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1841,PSIVISSIG0002_1841,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1078,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1842,PSIVISSIG0002_1842,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,987,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1843,PSIVISSIG0002_1843,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1139,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1844,PSIVISSIG0002_1844,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1031,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1845,PSIVISSIG0002_1845,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1846,PSIVISSIG0002_1846,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,132,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1847,PSIVISSIG0002_1847,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1074,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1848,PSIVISSIG0002_1848,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,802,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1849,PSIVISSIG0002_1849,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,664,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1850,PSIVISSIG0002_1850,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,45,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1851,PSIVISSIG0002_1851,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,228,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1852,PSIVISSIG0002_1852,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,408,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1853,PSIVISSIG0002_1853,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1100,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1854,PSIVISSIG0002_1854,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1057,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1855,PSIVISSIG0002_1855,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1382,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1856,PSIVISSIG0002_1856,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,465,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1857,PSIVISSIG0002_1857,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,754,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1858,PSIVISSIG0002_1858,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1061,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1859,PSIVISSIG0002_1859,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,565,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1860,PSIVISSIG0002_1860,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,75,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1861,PSIVISSIG0002_1861,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,622,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1862,PSIVISSIG0002_1862,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,423,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1863,PSIVISSIG0002_1863,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,157,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1864,PSIVISSIG0002_1864,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1352,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1865,PSIVISSIG0002_1865,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,836,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1866,PSIVISSIG0002_1866,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,312,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1867,PSIVISSIG0002_1867,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,749,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1868,PSIVISSIG0002_1868,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,919,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1869,PSIVISSIG0002_1869,62,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,256,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1870,PSIVISSIG0002_1870,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,245,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1871,PSIVISSIG0002_1871,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1874,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1872,PSIVISSIG0002_1872,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,106,0,Death,NA,DEATH
PSIVISSIG0002,1873,PSIVISSIG0002_1873,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,606,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1874,PSIVISSIG0002_1874,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,583,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1875,PSIVISSIG0002_1875,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,388,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1876,PSIVISSIG0002_1876,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,306,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1877,PSIVISSIG0002_1877,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,675,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1878,PSIVISSIG0002_1878,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1417,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1879,PSIVISSIG0002_1879,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,158,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1880,PSIVISSIG0002_1880,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,590,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1881,PSIVISSIG0002_1881,61,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,600,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1882,PSIVISSIG0002_1882,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,593,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1883,PSIVISSIG0002_1883,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,563,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1884,PSIVISSIG0002_1884,64,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1321,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1885,PSIVISSIG0002_1885,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1461,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1886,PSIVISSIG0002_1886,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,614,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1887,PSIVISSIG0002_1887,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1193,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1888,PSIVISSIG0002_1888,37,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,607,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1889,PSIVISSIG0002_1889,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1317,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1890,PSIVISSIG0002_1890,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1035,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1891,PSIVISSIG0002_1891,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,364,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1892,PSIVISSIG0002_1892,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,280,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1893,PSIVISSIG0002_1893,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1320,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1894,PSIVISSIG0002_1894,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,763,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1895,PSIVISSIG0002_1895,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,584,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1896,PSIVISSIG0002_1896,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1359,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1897,PSIVISSIG0002_1897,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1095,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1898,PSIVISSIG0002_1898,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,601,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1899,PSIVISSIG0002_1899,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,651,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1900,PSIVISSIG0002_1900,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,254,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1901,PSIVISSIG0002_1901,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,467,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1902,PSIVISSIG0002_1902,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,768,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1903,PSIVISSIG0002_1903,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,457,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1904,PSIVISSIG0002_1904,48,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1033,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1905,PSIVISSIG0002_1905,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,867,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1906,PSIVISSIG0002_1906,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1907,PSIVISSIG0002_1907,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,743,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1908,PSIVISSIG0002_1908,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,436,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1909,PSIVISSIG0002_1909,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,985,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1910,PSIVISSIG0002_1910,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1012,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1911,PSIVISSIG0002_1911,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,238,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1912,PSIVISSIG0002_1912,69,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,285,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1913,PSIVISSIG0002_1913,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,988,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1914,PSIVISSIG0002_1914,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,496,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1915,PSIVISSIG0002_1915,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,745,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1916,PSIVISSIG0002_1916,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,902,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1917,PSIVISSIG0002_1917,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1421,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1918,PSIVISSIG0002_1918,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1296,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1919,PSIVISSIG0002_1919,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,402,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1920,PSIVISSIG0002_1920,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,415,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1921,PSIVISSIG0002_1921,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1448,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1922,PSIVISSIG0002_1922,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,805,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1923,PSIVISSIG0002_1923,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,789,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1924,PSIVISSIG0002_1924,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1951,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1925,PSIVISSIG0002_1925,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,410,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1926,PSIVISSIG0002_1926,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,231,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1927,PSIVISSIG0002_1927,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,620,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1928,PSIVISSIG0002_1928,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1087,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1929,PSIVISSIG0002_1929,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,473,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1930,PSIVISSIG0002_1930,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,409,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1931,PSIVISSIG0002_1931,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,192,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1932,PSIVISSIG0002_1932,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,398,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1933,PSIVISSIG0002_1933,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,777,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1934,PSIVISSIG0002_1934,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,642,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1935,PSIVISSIG0002_1935,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,797,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1936,PSIVISSIG0002_1936,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,981,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1937,PSIVISSIG0002_1937,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,607,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1938,PSIVISSIG0002_1938,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,673,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1939,PSIVISSIG0002_1939,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,663,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1940,PSIVISSIG0002_1940,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,303,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1941,PSIVISSIG0002_1941,65,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,246,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1942,PSIVISSIG0002_1942,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,741,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1943,PSIVISSIG0002_1943,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1022,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1944,PSIVISSIG0002_1944,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,73,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1945,PSIVISSIG0002_1945,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,742,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1946,PSIVISSIG0002_1946,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1323,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1947,PSIVISSIG0002_1947,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1075,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1948,PSIVISSIG0002_1948,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,849,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1949,PSIVISSIG0002_1949,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1453,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1950,PSIVISSIG0002_1950,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,261,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1951,PSIVISSIG0002_1951,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,180,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1952,PSIVISSIG0002_1952,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,349,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1953,PSIVISSIG0002_1953,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,539,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1954,PSIVISSIG0002_1954,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1219,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1955,PSIVISSIG0002_1955,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,698,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1956,PSIVISSIG0002_1956,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1295,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1957,PSIVISSIG0002_1957,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1685,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1958,PSIVISSIG0002_1958,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1317,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1959,PSIVISSIG0002_1959,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,338,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1960,PSIVISSIG0002_1960,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1134,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1961,PSIVISSIG0002_1961,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,668,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1962,PSIVISSIG0002_1962,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1726,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1963,PSIVISSIG0002_1963,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,845,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1964,PSIVISSIG0002_1964,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,0,Death,NA,DEATH
PSIVISSIG0002,1965,PSIVISSIG0002_1965,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,578,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1966,PSIVISSIG0002_1966,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1967,PSIVISSIG0002_1967,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,137,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1968,PSIVISSIG0002_1968,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,623,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1969,PSIVISSIG0002_1969,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1970,PSIVISSIG0002_1970,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,297,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1971,PSIVISSIG0002_1971,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,519,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1972,PSIVISSIG0002_1972,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1973,PSIVISSIG0002_1973,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,572,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1974,PSIVISSIG0002_1974,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,400,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1975,PSIVISSIG0002_1975,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,651,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1976,PSIVISSIG0002_1976,58,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,403,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1977,PSIVISSIG0002_1977,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,251,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1978,PSIVISSIG0002_1978,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1093,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1979,PSIVISSIG0002_1979,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,463,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1980,PSIVISSIG0002_1980,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,118,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1981,PSIVISSIG0002_1981,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,635,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1982,PSIVISSIG0002_1982,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,899,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1983,PSIVISSIG0002_1983,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,373,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1984,PSIVISSIG0002_1984,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,831,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1985,PSIVISSIG0002_1985,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1166,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1986,PSIVISSIG0002_1986,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1134,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1987,PSIVISSIG0002_1987,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,736,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1988,PSIVISSIG0002_1988,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,297,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1989,PSIVISSIG0002_1989,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1304,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1990,PSIVISSIG0002_1990,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,468,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1991,PSIVISSIG0002_1991,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,148,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1992,PSIVISSIG0002_1992,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1043,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1993,PSIVISSIG0002_1993,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,356,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1994,PSIVISSIG0002_1994,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,48,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1995,PSIVISSIG0002_1995,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1012,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1996,PSIVISSIG0002_1996,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,560,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1997,PSIVISSIG0002_1997,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,441,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1998,PSIVISSIG0002_1998,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1141,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1999,PSIVISSIG0002_1999,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,412,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2000,PSIVISSIG0002_2000,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,260,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2001,PSIVISSIG0002_2001,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,556,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2002,PSIVISSIG0002_2002,48,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1036,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2003,PSIVISSIG0002_2003,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1437,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2004,PSIVISSIG0002_2004,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,160,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2005,PSIVISSIG0002_2005,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,387,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2006,PSIVISSIG0002_2006,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,730,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2007,PSIVISSIG0002_2007,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1027,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2008,PSIVISSIG0002_2008,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,437,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2009,PSIVISSIG0002_2009,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,359,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2010,PSIVISSIG0002_2010,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,891,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2011,PSIVISSIG0002_2011,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1786,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2012,PSIVISSIG0002_2012,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,573,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2013,PSIVISSIG0002_2013,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,133,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2014,PSIVISSIG0002_2014,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2015,PSIVISSIG0002_2015,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,872,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2016,PSIVISSIG0002_2016,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1167,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2017,PSIVISSIG0002_2017,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,78,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2018,PSIVISSIG0002_2018,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,640,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2019,PSIVISSIG0002_2019,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,859,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2020,PSIVISSIG0002_2020,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,69,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2021,PSIVISSIG0002_2021,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1467,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2022,PSIVISSIG0002_2022,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,691,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2023,PSIVISSIG0002_2023,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,569,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2024,PSIVISSIG0002_2024,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,241,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2025,PSIVISSIG0002_2025,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,664,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2026,PSIVISSIG0002_2026,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,853,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2027,PSIVISSIG0002_2027,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1422,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2028,PSIVISSIG0002_2028,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,615,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2029,PSIVISSIG0002_2029,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,178,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2030,PSIVISSIG0002_2030,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,609,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2031,PSIVISSIG0002_2031,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,939,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2032,PSIVISSIG0002_2032,55,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,708,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2033,PSIVISSIG0002_2033,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1092,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2034,PSIVISSIG0002_2034,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,577,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2035,PSIVISSIG0002_2035,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,315,0,PD,NA,DEATH
PSIVISSIG0002,2036,PSIVISSIG0002_2036,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,584,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,2037,PSIVISSIG0002_2037,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2038,PSIVISSIG0002_2038,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1349,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2039,PSIVISSIG0002_2039,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,127,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2040,PSIVISSIG0002_2040,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,756,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2041,PSIVISSIG0002_2041,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1412,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2042,PSIVISSIG0002_2042,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,221,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2043,PSIVISSIG0002_2043,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,978,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2044,PSIVISSIG0002_2044,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,404,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2045,PSIVISSIG0002_2045,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1528,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2046,PSIVISSIG0002_2046,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,849,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2047,PSIVISSIG0002_2047,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,237,0,Death,NA,DEATH
PSIVISSIG0002,2048,PSIVISSIG0002_2048,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1142,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2049,PSIVISSIG0002_2049,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,971,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2050,PSIVISSIG0002_2050,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1399,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2051,PSIVISSIG0002_2051,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,149,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2052,PSIVISSIG0002_2052,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,896,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2053,PSIVISSIG0002_2053,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1414,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2054,PSIVISSIG0002_2054,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1363,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2055,PSIVISSIG0002_2055,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,774,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2056,PSIVISSIG0002_2056,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,578,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2057,PSIVISSIG0002_2057,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,628,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2058,PSIVISSIG0002_2058,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,554,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2059,PSIVISSIG0002_2059,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,161,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2060,PSIVISSIG0002_2060,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,402,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2061,PSIVISSIG0002_2061,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1017,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2062,PSIVISSIG0002_2062,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,676,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2063,PSIVISSIG0002_2063,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1502,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2064,PSIVISSIG0002_2064,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,531,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2065,PSIVISSIG0002_2065,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,467,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2066,PSIVISSIG0002_2066,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1136,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2067,PSIVISSIG0002_2067,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1191,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2068,PSIVISSIG0002_2068,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1383,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2069,PSIVISSIG0002_2069,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,751,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2070,PSIVISSIG0002_2070,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,231,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2071,PSIVISSIG0002_2071,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,270,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2072,PSIVISSIG0002_2072,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,291,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2073,PSIVISSIG0002_2073,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,742,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2074,PSIVISSIG0002_2074,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,192,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2075,PSIVISSIG0002_2075,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,982,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2076,PSIVISSIG0002_2076,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,620,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2077,PSIVISSIG0002_2077,46,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,260,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2078,PSIVISSIG0002_2078,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,177,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2079,PSIVISSIG0002_2079,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,868,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2080,PSIVISSIG0002_2080,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1506,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2081,PSIVISSIG0002_2081,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,416,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2082,PSIVISSIG0002_2082,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1297,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2083,PSIVISSIG0002_2083,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,706,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2084,PSIVISSIG0002_2084,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,647,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,2085,PSIVISSIG0002_2085,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,747,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2086,PSIVISSIG0002_2086,71,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2087,PSIVISSIG0002_2087,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,427,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2088,PSIVISSIG0002_2088,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,430,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2089,PSIVISSIG0002_2089,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,313,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2090,PSIVISSIG0002_2090,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,119,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2091,PSIVISSIG0002_2091,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,635,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2092,PSIVISSIG0002_2092,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,281,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2093,PSIVISSIG0002_2093,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,265,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2094,PSIVISSIG0002_2094,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,655,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2095,PSIVISSIG0002_2095,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1058,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2096,PSIVISSIG0002_2096,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,730,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2097,PSIVISSIG0002_2097,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,38,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2098,PSIVISSIG0002_2098,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1374,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,2099,PSIVISSIG0002_2099,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1042,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2100,PSIVISSIG0002_2100,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1313,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2101,PSIVISSIG0002_2101,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,475,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2102,PSIVISSIG0002_2102,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,227,0,Death,NA,DEATH
PSIVISSIG0002,2103,PSIVISSIG0002_2103,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,182,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2104,PSIVISSIG0002_2104,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,307,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2105,PSIVISSIG0002_2105,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,309,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2106,PSIVISSIG0002_2106,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,354,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2107,PSIVISSIG0002_2107,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,815,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2108,PSIVISSIG0002_2108,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1798,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2109,PSIVISSIG0002_2109,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1787,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2110,PSIVISSIG0002_2110,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,847,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2111,PSIVISSIG0002_2111,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,221,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2112,PSIVISSIG0002_2112,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,429,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2113,PSIVISSIG0002_2113,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,574,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2114,PSIVISSIG0002_2114,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,524,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2115,PSIVISSIG0002_2115,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,327,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2116,PSIVISSIG0002_2116,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1161,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,2117,PSIVISSIG0002_2117,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,903,0,Death,NA,DEATH
PSIVISSIG0002,2118,PSIVISSIG0002_2118,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,68,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2119,PSIVISSIG0002_2119,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,914,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2120,PSIVISSIG0002_2120,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,237,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2121,PSIVISSIG0002_2121,71,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,237,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2122,PSIVISSIG0002_2122,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,184,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2123,PSIVISSIG0002_2123,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,732,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2124,PSIVISSIG0002_2124,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,656,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2125,PSIVISSIG0002_2125,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,396,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2126,PSIVISSIG0002_2126,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,69,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2127,PSIVISSIG0002_2127,60,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,305,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2128,PSIVISSIG0002_2128,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,648,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2129,PSIVISSIG0002_2129,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,479,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2130,PSIVISSIG0002_2130,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,555,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2131,PSIVISSIG0002_2131,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,178,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2132,PSIVISSIG0002_2132,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,555,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2133,PSIVISSIG0002_2133,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,903,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2134,PSIVISSIG0002_2134,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1816,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2135,PSIVISSIG0002_2135,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,911,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2136,PSIVISSIG0002_2136,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1420,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2137,PSIVISSIG0002_2137,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,235,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2138,PSIVISSIG0002_2138,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,256,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2139,PSIVISSIG0002_2139,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1503,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2140,PSIVISSIG0002_2140,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,259,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2141,PSIVISSIG0002_2141,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,761,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2142,PSIVISSIG0002_2142,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,182,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2143,PSIVISSIG0002_2143,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,464,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2144,PSIVISSIG0002_2144,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1859,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,2145,PSIVISSIG0002_2145,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,466,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2146,PSIVISSIG0002_2146,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,621,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2147,PSIVISSIG0002_2147,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1020,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2148,PSIVISSIG0002_2148,57,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,577,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2149,PSIVISSIG0002_2149,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,766,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2150,PSIVISSIG0002_2150,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1323,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2151,PSIVISSIG0002_2151,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,857,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2152,PSIVISSIG0002_2152,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,295,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2153,PSIVISSIG0002_2153,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,849,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2154,PSIVISSIG0002_2154,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,867,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2155,PSIVISSIG0002_2155,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1030,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2156,PSIVISSIG0002_2156,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,397,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2157,PSIVISSIG0002_2157,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1365,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,2158,PSIVISSIG0002_2158,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,573,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2159,PSIVISSIG0002_2159,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,680,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2160,PSIVISSIG0002_2160,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,239,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2161,PSIVISSIG0002_2161,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,985,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2162,PSIVISSIG0002_2162,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,606,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2163,PSIVISSIG0002_2163,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,252,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2164,PSIVISSIG0002_2164,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,609,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2165,PSIVISSIG0002_2165,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1100,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2166,PSIVISSIG0002_2166,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,30,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2167,PSIVISSIG0002_2167,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,307,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2168,PSIVISSIG0002_2168,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,110,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2169,PSIVISSIG0002_2169,72,Negative,2,Hormone receptor negative,PRIOR USE,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,722,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2170,PSIVISSIG0002_2170,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,45,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2171,PSIVISSIG0002_2171,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,562,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2172,PSIVISSIG0002_2172,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,971,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2173,PSIVISSIG0002_2173,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1188,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2174,PSIVISSIG0002_2174,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,369,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2175,PSIVISSIG0002_2175,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,665,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2176,PSIVISSIG0002_2176,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,648,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2177,PSIVISSIG0002_2177,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2178,PSIVISSIG0002_2178,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,173,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2179,PSIVISSIG0002_2179,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,498,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2180,PSIVISSIG0002_2180,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,550,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2181,PSIVISSIG0002_2181,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,461,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2182,PSIVISSIG0002_2182,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2183,PSIVISSIG0002_2183,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,624,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2184,PSIVISSIG0002_2184,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,420,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2185,PSIVISSIG0002_2185,61,Positive,1,Hormone receptor positive,PRIOR USE,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,600,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2186,PSIVISSIG0002_2186,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2187,PSIVISSIG0002_2187,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1177,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2188,PSIVISSIG0002_2188,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,441,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2189,PSIVISSIG0002_2189,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,684,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2190,PSIVISSIG0002_2190,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,344,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2191,PSIVISSIG0002_2191,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2192,PSIVISSIG0002_2192,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1193,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2193,PSIVISSIG0002_2193,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,948,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2194,PSIVISSIG0002_2194,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1173,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2195,PSIVISSIG0002_2195,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,784,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2196,PSIVISSIG0002_2196,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,907,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2197,PSIVISSIG0002_2197,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,796,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2198,PSIVISSIG0002_2198,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,802,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2199,PSIVISSIG0002_2199,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,582,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
